[User] <|image|>Translate the table into Markdown format.

[Assistant]
<md> | Test flavonoid or flavonoids combination | S. aureus | MRSA clinical isolates (n = 100) |
 | --- | --- | --- |
 | M | 0 | 0 |
 | R | 0 | 0 |
 | Q | 13.5 ± 0.21 | 13.33 ± 0.26 |
 | M + R | 11.5 ± 0.22 | 11.58 ± 0.21 |
 | Q + R | 0 | 0 |
 | Q + M | 0 | 0 |
 | M + Q + R | 16.5 ± 0.21 | 16.23 ± 0.26 | </md>


[User] <|image|>Express the illustration as Markdown code.

[Assistant]
<md> | Stimulation | Right-sided | Left-sided | Bilateral |
 | --- | --- | --- | --- |
 | Patient 1 | 90% | 95% | 10% |
 | Patient 2 | 100% | 85% | 0% |
 | Patient 3 | 100% | 85% | 0% |
 | Patient 4 | 85% | 15% | 0% |
 | Control group (average) | 100% | 100% | 100% | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> |  | <COLSPAN=3> p.A143T Fabry patients | <COLSPAN=3> Missense mutation patients |
 |  | Total (n = 25) | Female (n = 15) | Male (n = 10) | Total (n = 58) | Female (n = 39) | Male (n = 19) |
 | --- | --- | --- | --- | --- | --- | --- |
 | gastrointestinal pain, n | 12 (48.0) | 8 (53.3)* | 4 (40.0) | 11 (20.0) | 6 (16.2) | 5 (27.8) |
 | diarrhea, n | 8 (32.0) | 6 (40.0)** | 2 (20.0) | 5 (9.1) | 2 (5.4) | 3 (16.7) |
 | tinnitus, n | 7 (29.2) | 4 (28.6) | 3 (30.0) | 6 (10.7) | 6 (16.2) | 0 (0.0) |
 | neuropathic pain, n | 7 (28.0) | 4 (26.7) | 3 (30.0) | 26 (45.6) | 18 (47.4) | 8 (42.1) |
 | hypohidrosis, n | 6 (24.0) | 4 (26.7) | 2 (20.0) | 18 (32.1) | 11 (29.0) | 7 (38.9) |
 | fatigue, n | 5 (20.0) | 4 (26.7) | 1 (10.0) | 10 (18.9) | 8 (23.5) | 2 (10.5) |
 | hypacusis, n | 3 (12.5) | 1 (7.1) | 2 (20.0) | 5 (8.8) | 5 (13.2) | 0 (0.0) |
 | dyspnea, n | 3 (12.0) | 3 (20.0) | 0 (0.0) | 12 (21.1) | 8 (21.1) | 4 (21.1) |
 | edema, n | 1 (4.2) | 1 (6.7) | 0 (0.0) | 2 (3.6) | 0 (0.0) | 2

[Assistant]
(10.5) |
 | cornea verticillata, n | 0 (0.0) | 0 (0.0) | 0 (0.0) | 9 (19.6) | 8 (29.6)* | 1 (5.3) |
 | LVEF, % | 63.1 ± 6.4 | 60.9 ± 6.2 | 66.2 ± 5.6 | 63.2 ± 9.6 | 64.5 ± 9.8 | 60.6 ± 8.8 | </md>


[User] <|image|>Transform the diagram into Markdown format.

[Assistant]
<md> | Features | n | % |
 | --- | --- | --- |
 | Age (years) | <COLSPAN=2>  |
 | ≤65 | 561 | 79.3 |
 | >65 | 146 | 20.7 |
 | Gender | <COLSPAN=2>  |
 | Male | 454 | 64.2 |
 | Female | 253 | 35.8 |
 | Symptoms initially presented | <COLSPAN=2>  |
 | Cough | 597 | 84.4 |
 | Shortness of breath | 244 | 34.5 |
 | Chest pain | 243 | 34.4 |
 | Hemoptysis or blood in phlegm | 233 | 33.0 |
 | Hoarseness | 30 | 4.2 |
 | KPS (Karnofsky Performance Status) | <COLSPAN=2>  |
 | >80 point | 543 | 76.8 |
 | ≤80 points | 164 | 23.2 |
 | Smoking history | <COLSPAN=2>  |
 | Yes | 442 | 62.5 |
 | No | 265 | 37.5 |
 | Family history of cancer | <COLSPAN=2>  |
 | Yes | 116 | 16.4 |
 | No | 591 | 83.6 |
 | Thoracic irradiation | <COLSPAN=2>  |
 | Yes | 294 | 41.6 |
 | No | 413 | 58.4 |
 | Surgery | <COLSPAN=2>  |
 | Yes | 25 | 3.5 |
 | No | 682 | 96.5 |
 | Chemotherapy cycles | <COLSPAN=2>  |
 | <4 | 332 | 47.0 |
 | ≥4 | 375 | 53.0 |
 | Metastatic sites | <COLSPAN=2>  |
 | <2 | 642 | 90.8 |
 | ≥2 | 65 | 9.2 |
 | Stage | <COLSPAN=2>  |
 | LD | 419 | 59.3 |
 | ED | 288 | 40.7 | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Method | Pre-counselling | Post-counselling | Difference | <ROWSPAN=2> p-value (McNemar’s test) |
 | n (%) | n (%) | (95 % CI) |
 | --- | --- | --- | --- | --- |
 | Pill | 1207 (64.5) | 1199 (64.1) | −0.4 (−2.6 to 1.8) | 0.71 |
 | Transdermal patch | 60 (3.2) | 131 (7.0) | 3.8 (2.6 to 5.0) | <0.0001 |
 | Vaginal ring | 97 (5.2) | 397 (21.2) | 16.0 (14.3 to 17.8) | <0.0001 |
 | Other method | 171 (9.1) | 104 (5.6) | −3.6 (−5.0 to −2.2) | <0.0001 |
 | Undecided | 336 (18.0) | 40 (2.1) | −15.8 (−17.6 to 14.1) | <0.0001 | </md>


[User] <|image|>Render the image in Markdown format.

[Assistant]
<md> |  | Normal boys | Intellectually disabled boys | Student’s t- test | P-value |
 | --- | --- | --- | --- | --- |
 | Anxiety/Depression | 3.12 (± 1.70) | 6.23 (± 3.45) | 1.08 | 0.002 |
 | Attention disorder | 4.30 (± 2.23) | 5.76 (± 2.61) | 2.14 | 0.013 |
 | Aggressiveness | 3.57 (± 6.12) | 6.12 (± 2.18) | 3.11 | 0.002 |
 | Externalizing | 3.54 (± 3.23) | 3.23 (± 1.53) | 2.08 | 0.310 |
 | Social problems | 6.44 (± 8.17) | 8.17 (± 3.51) | 2.11 | 0.002 | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | Concepts | Definitions | Examples |
 | --- | --- | --- |
 | Role | Function assumed by the nurse, modulated by professional norms, a legislative framework, a scope of practice and a social system. | Primary care nurses for patients with chronic conditions |
 | Domain | Set of activities of the same nature requiring specific knowledge and expertise. | Patient care management |
 | Activity | Actions undertaken by the nurse to help a patient go from a current state of health to the one described in expected results. |

[Assistant] - Providing nursing care- Referring the patient to community resources- Performing intervention plan- Communicating with the patient’s healthcare providers | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | <ROWSPAN=2> Species | <COLSPAN=2> Tregs | <COLSPAN=2> CD4+ T cells that produce IL-17 |
 | Promoting factors | Inhibiting factors | Promoting factors | Inhibiting factors |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=7> Mouse | IL-2 | IL-6 | IL-6 | TGF-β (high concentration) |
 | TGF-β | TNF-α | TGF-β (low concentration) | IL-2 |
 | IL-10 | IL-1β | IL-21 | IL-4 |
 | <ROWSPAN=4> Lower affinity of TCR | <ROWSPAN=4>  | IL-23 | IL-12

[Assistant]
|
 | Saturated fatty acids | IFN-γ |
 | <ROWSPAN=2> IL-1β | Polyunsaturated fatty acids |
 | Estradiol |
 | <ROWSPAN=7> Human | Antigen or mitogen | IL-6 | IL-6 | TGF-β |
 | IL-2 | IL-21 | TGF-β (low concentrated) | IL-4 |
 | <ROWSPAN=5> TGF-β | IL-23 | IL-21 | IL-12 |
 | IL-17 | IL-23 | IFN-γ |
 | TNF-α | <ROWSPAN=3>  | <ROWSPAN=3>  |
 | IL-1β |
 | RANTES |
 | <ROWSPAN=4> Canine (dogs) | Con-A | IL-6 | IL-6 | TGF-β |
 | IL-2 | IL-1β | IL-1β | <ROWSPAN=3>  |
 | TGF-β | <ROWSPAN=2>  | <ROWSPAN=2> TFG-β |
 | IL-10 |
 | <ROWSPAN=4> Feline (cats) | Mitogens | IL-6 | IL-1β | TGF-β |
 | LPS and flagellin | IL-1β | IL-6 | <ROWSPAN=3> IL-10 |
 | <ROWSPAN=2> IL-2 | <ROWSPAN=2>  | TGF-β |
 | IL-21 |
 | Bovine | Antigen or mitogens along with IL-10, TGF-β | IL-6 | IL-23 | Progesterone, IFN-γ | </md>


[User] <|image|>Convert the table to Markdown syntax.

[Assistant]
<md> | Variable | Hazard Ratio | 95% CI | P-value |
 | --- | --- | --- | --- |
 | Gender (male) | 1.09 | 0.70 - 1.70 | 0.69 |
 | Age (years) | 1.01 | 0.99 - 1.03 | 0.28 |
 | Tobacco use (yes) | 1.08 | 0.70 - 1.67 | 0.72 |
 | Alcohol use (daily or weekly) | 1.00 | 0.67 -- 1.47 | 0.98 |
 | Family history of UGI cancer (yes) | 1.00 | 0.72 - 1.40 | 1.00 |
 | Tumor grade (I -- IV) | 1.18 | 0.90 - 1.54 | 0.24 |
 | Tumor stage (1 -- 4) | 1.92 | 1.14 - 3.23 | 0.01 |
 | Metastasis (yes) | 2.17 | 1.59 - 2.95 | < 0.0001 |
 | Degree differentiation (poor) | 1.07 | 0.76 - 1.50 | 0.71 | </md>


[User] <|image|>Convert the figure to Markdown syntax.

[Assistant]
<md> | Species | C. brenneri | C. remanei | C. briggsae | C. japonica | B. malayi | P. pacificus |
 | --- | --- | --- | --- | --- | --- | --- |
 | Genome Size (Mb) | ~150 | ~135 | 104 | ~135 | 90 | 169 |
 | Gene Count | unknown | ~26,000 | 19,500 | unknown | 18,500 | 23,500 |
 | Total Bases | 21,261,492 | 11,679,749 | 3,853,734 | 4,943,716 | 9,773,484 | 11,396,247 |
 | Repeat Length | 6,929 | 6,921 | 6,830 | 6,825 | 7,330 | 6,261 |
 | Mean Coverage | 3,068 | 1,688 | 564 | 724 | 1,333 | 1,820 |
 | Coverage Depth | 9.5 | 9.2 | 10 | 6.3 | 8.9 | 8.9 |
 | Repeat Estimate | 323 | 183 | 56 | 115 | 150 | 205 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Risk Factors | OR | 95% CI | p |
 | --- | --- | --- | --- |
 | Univariate analysis |  |  |  |
 | Thiamine level | 0.98 | 0.97–1.00 | 0.074 |
 | Zinc level | 0.98 | 0.95–1.00 | 0.067 |
 | Chromium level | 1.05 | 0.97–1.14 | 0.211 |
 | Selenium level | 0.98 | 0.94–1.01 | 0.323 |
 | Multiple micronutrients deficiency | 2.98 | 1.04–8.53 | 0.041 |
 | NRS-2002 score on admission | 3.56 | 1.97–6.43 | <0.001 |
 | Age | 1.03 | 1.005–1.07 | 0.022 |
 | CRP | 1.01 | 1.004–1.019 | 0.002 |
 | BMI | 0.97 | 0.87–1.08 | 0.589 |
 | Gender | 0.94 | 0.35–2.48 | 0.907 |
 | Glucose | 1.01 | 1.004–1.019 | 0.004 |
 | Urea | 1.02 | 1.004–1.04 | 0.016 |
 |

[Assistant]
Leukocyte count | 1.00 | 1.00–1.00 | 0.002 |
 | Hemoglobin | 0.79 | 0.62–1.01 | 0.064 |
 | Albumin | 0.06 | 0.01–0.21 | <0.001 |
 | LDH | 1.00 | 0.99–1.007 | 0.183 |
 | Multiple analysis |  |  |  |
 | Albumin | 0.02 | 0.002–0.260 | 0.002 |
 | NRS-2002 on admission | 2.74 | 1.23–6.08 | 0.013 |
 | Glucose | 1.01 | 1.003–1.03 | 0.018 | </md>


[User] <|image|>Transform the photo into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Ref | <ROWSPAN=2> Gene | <ROWSPAN=2> Function | <COLSPAN=3> Frequency % |
 | MF | ET | PV |
 | --- | --- | --- | --- | --- | --- |
 | [30] | JAK2 | Tyrosine kinase | 55–60 | 50–60 | 95–97 |
 | [31] | CALR | Endoplasmic chaperone | 25–30 | 20–25 | <1 |
 | [32] | MPL | Growth factor receptor | 5–10 | 3–5 | <1 |
 | [30] | SF3B1 | Splicing regulator | 5–10 | ~1 | ~1 |
 | [33] | TP53 | DNA damage response | 2–4 | <1 | <1 |
 | [34] | CBL | E3 ubiquitin ligase | 5–10 | 0–2 | Rare |
 | [35] | DNMT3A | DNA methyltransferase | 5–12 | 1–5 | 5–10 |
 | [35] | TET2 | Methylcytosine dioxygenase | 10–20 | 5 | 10–20 |
 | [36] | EZH2 | Chromatin regulator | 5–10 | ~2 | ~2 |
 | [37] | IDH1/2 | Isocitrate dehydrogenase | 3–5 | <1 | ~2 |
 | [37] | ASXL1 | Chromatin regulator | 15–35 | 5–10 | 2–7 | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | Virus | Sequence Data Available | Length of Genome (nt) | Length of 5’ UTR (nt) | Length of 3’ UTR (nt) | a Genbank Accession No. |
 | --- | --- | --- | --- | --- | --- |
 | Barkedji virus | Almost entire ORF | b - | - | - | KC496020 |
 | Chaoyang virus | Genome | 10,733 | 99 | 326 | NC_017086 |
 | Donggang virus | Genome | 10,791 | 113 | 343 | NC_016997 |
 | Ilomantsi virus | ORF | - | - | - | NC_024805 |
 | Lammi virus | ORF | - | - | - | KC692068 |
 | Marisma mosquito virus | Partial NS5 | - | - | - | JN603190 |
 | Nanay virus | Partial E and NS5 | - | - | - | JX627335 |
 | Nhumirim virus | Genome | 10,891 | 102 | 451 | NC_024017 |
 | Nounané virus | ORF | - | - | - | EU159426 | </md>


[User] <|image|>Convert the table into Markdown language.

[Assistant]
<md> | Column # | 1 | 2 | 3 | 4 | 5 |
 | Exercise | Pr Br Floor | Pr Br Ball | Side Bridge | Su Br Ball | Su Br Floor |
 | --- | --- | --- | --- | --- | --- |
 | IO Avg | 29.5 | 39.8 | 42.5 | 19.7 | 12.3 |
 | Stdev | 18.8 | 23.9 | 25.2 | 15.8 | 9.5 |
 | Different From* | - | 4,5 | 4,5 | 2,3 | 2,3 |
 | RA Avg | 26.6 | 55.9 | 24.4 | 6.05 | 5.84 |
 | Stdev | 11.1 | 28.8 | 11.7 | 1.3 | 1.1 |
 | Different From* | 2,4,5 | 1,3,4,5 | 2,4,5 | 1,2,3 | 1,2,3 |
 | EO Avg | 44.6 | 62.5 | 46.1 | 10.6 | 7.8 |
 | Stdev | 14.8 | 26.3 | 15.4 | 5.7 | 6.3 |
 | Different From* | 2,4,5 | 1,3,4,5 | 2,4,5 | 1,2,3 | 1,2,3 |
 | ES Avg | 4.98 | 5.00 | 25.7 | 27.4 | 25.01 |
 | Stdev | 1.05 | 1.46 | 11.3 | 7.56 | 9.02 |
 | Different From* | 3,4,5 | 3,4,5 | 1,2 | 1,2 | 1,2 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Sample | Age (years) | Right Hand (kg) | Left Hand (kg) | Sum of Two Hands (kg) | Reference |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Males |
 | Spanish (n = 74) | 14.7 ± 1.1 | 37.7 ± 11.9 |  |  | (Torres-Luque et al., 2015) [33] |
 | Tunisians national (n = 12) | 18.6 ± 2.4 | ~54 |  |  | (Souissi et al., 2013) [38] |
 | Cypriots competitive (n = 11) | 20 ± 6 | 46.5 ± 8.8 | 42.0 ± 8.8 |

[Assistant]
88.5 a | (Papacosta et al., 2013) [40] |
 | Spanish national (n = 12) | 22.0 ± 3.2 | 57.6 ± 6.9 | 55.4 ± 7.4 | 113 a | (Bonitch-Góngora et al., 2012) [43] |
 | Spanish national (n = 14) | 22.9 | 48.4 | 46.5 | 94.9 | (Morales et al., 2014) [47] |
 | Portuguese national (n = 27) | 23.2 ± 2.8 | 50.8 ± 7.4 b |  |  | (Silva et al., 2011) [49] |
 | Europeans elite (n = 10) | 25.6 ± 3.6 | 64.3 | 69.0 | 133.3 a | (Drid et al., 2015) [51] |
 | Brazilian recreational (n = 180) | 25.7 ± 4.9 |  |  | 101 ± 15 | (Schwartz et al., 2015) [52] |
 | Brazilian competitive (n = 22) | 22.5 ± 3.9 | 51.4 ± 8.2 c | 51.4 ± 7.9 | 102.8 a | (Ache Dias et al., 2012) [45] |
 | French competitive (n = 13) | adults | 50.0 | 49.6 | 99.6 a | (Franchini et al., 2015) [53] |
 | <COLSPAN=6> Females |
 | Spanish (n = 72) | 14.5 ± 1.2 | 26.6 ± 7.4 |  |  | (Torres-Luque et al., 2015) [33] | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> | The potential approaches to disrupt the Hsp90-Cdc37-client protein interaction | Related mechanisms | References |
 | --- | --- | --- |
 | <COLSPAN=3> Targeting Cdc37 |
 | siRNAs or shRNA | Silencing Cdc37 | [56, 57] |
 | <COLSPAN=3> Targeting Cdc37-client interaction |
 | 4,5,6,7-Tetrabromobenzotriazole | CK2 inhibitors, suppressing Cdc37 phosphorylation at Ser13 site | [59] |
 | PP5 mutation | Suppressing Cdc37 dephosphorylation | [48] |
 | Vemurafenib | B-raf inhibitor. Antagonize Cdc37 interaction with kinases | [67] |
 | Lapatinib | EGFR/HER2 inhibitor. Antagonize Cdc37 interaction with kinases | [67] |
 | <COLSPAN=3> Targeting Hsp90-Cdc37 interaction |
 | Celastrol | Blocking the critical interaction of Hsp90 at Glu33 and Cdc37 at Arg167 | [68, 69] |
 | Sulforaphane | Disrupting the formation of Hsp90-Cdc37 complex by direct modification of specific amino acids residues of Hsp90 | [70] |
 | FW-04-804 | Binding sites at Gln133 and Glu47/Arg46 of Hsp90 | [71, 72] |
 | Withaferin A | Blocking several H-bond between Hsp90-Cdc37 interaction, like Ser113 (Hsp90)-Gln208 (Cdc37) bond and Gln133 (Hsp90)-Arg166 (Cdc37) bond | [73–75] |
 | Kongensin A | Covalently binds to a cysteine 420 in the middle domain of Hsp90 and dissociates Hsp90 from Cdc37 | [76, 77] |
 | Platycodin D | H-bond connection with Hsp90 at Arg32 and Phe200 and Cdc37 at Asp169 and Asp170 | [78, 79] |
 | Pep-1 | Cdc37-derived peptides, bound to Hsp90 N-terminal domain and inhibited Hsp90 ATPase activity | [80] | </md>


[User] <|image|>Express the image as Markdown code.

[Assistant]
<md> | Gene | Description | Ref | 14-A ST124 | 14-B ST555 |
 | --- | --- | --- | --- | --- |
 | SP 0071 | immunoglobulin A1 protease | [6, 8] | - | + |
 | SP 0143 | Hypothetical protein | [8] | - | + |
 | SP 0265 | bgla; 6 phospho beta glucosidase | [6] | - | + |
 | SP 0396 | mtlf; Mannitol specific enzyme IIA component | [6] | - | + |
 | SP 0474 | pts eii; Phosphotransferase system sugar specific EII component | [6] | - | + |
 | SP 1321 | v type sodium ATP synthase subunit K | [6] | - | + |
 | SP 1328 | sodium:solute symporter family protein | [6] | - | + |
 | SP 0268 | alkaline amylopullulanase putative | [6] | +TIGR4 | +R6 |
 | SP 0629 | conserved hypothetical protein | [7] | +TIGR4 | +R6 |
 | SP 0933 | pyrroline 5 carboxylate reductase | [7] | +TIGR4 | +R6 |
 | SP 1018 | tdk; Thymidine kinase | [6] | +TIGR4 | +R6 |
 | SP 1029 | RNA methyltransferase TrmA family | [6] | +TIGR4 | +R6 |
 | SP 1343 | ptrb; Protease II (oligopeptidase B) | [6] | + | - |
 | SP 1344 | Conserved hypothetical protein | [6] | + | - |
 | SP 1433 | Hypothetical protein | [6] | + | - |
 | SP 1434 | ABC transporter ATP binding/permease protein | [6] | + | - |
 | SP 2095 | Conserved hypothetical protein | [6] | + | - |
 | SP 2164 | pts eii; Phosphotransferase system sugar specific EII component | [6] | + | - | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> | <COLSPAN=3> Negative binomial component | <COLSPAN=3> Logistic component |
 | <COLSPAN=3> Incidence rate ratios (IRR) | <COLSPAN=3> Odds ratio (OR) for not having malaria |
 |  | IRR (95% CI) | P |  | OR (95% CI) | p |
 | --- | --- | --- | --- | --- | --- |
 | IPTi | 0.87 (0.78, 0.97) | 0.01 | IPTi | 1.16 (0.46, 2.89) | 0.755 |
 | Zone of residence |  |  | Zone of residence |  |  |
 | urban | - |  | urban | - |  |
 | rocky highland | 1.22 (0.95, 1.58) | 0.123 | rocky highland | 0.22 (0.02, 2.85) | 0.247 |
 | lowland rural | 1.27 (1.08, 1.51) | 0.005 | lowland rural | 0.04 (0, 0.97) | 0.048 |
 | irrigated rural | 1.27 (1.05, 1.54) | 0.016 | irrigated rural | 0.08 (0.01, 0.85) | 0.036 |
 | Season of birth |  |  | - |  |  |
 | late wet | - |  |  |  |  |
 | early dry | 0.99 (0.88, 1.10) | 0.8 |  |  |  |
 | late dry | 0.86 (0.77, 0.97) | 0.015 |  |  |  |
 | early wet | 0.94 (0.84, 1.06) | 0.305 |  |  |  |
 | Sex (female vs male) | 0.96 (0.90, 1.04) | 0.335 | - |  |  | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> |  | <COLSPAN=3> Country of origin |
 | --- | --- | --- | --- |
 | Age group(years) | Syrian (rate per 1,000)b | Afghanistann (rate per 1,000)b | Iraqn (rate per 1,000)b |
 | 0–4 | 43 (8.8) | 4(2.1) | 2 (1.8) |

[Assistant]
| 5–9 | 55 (11.9) | 1 (0.5) | 3 (2.5) |
 | 10–14 | 32 (9.5) | 2 (1.2) | 4 (4.2) |
 | 15–29 | 22 (2.2) | 1 (0.1) | 0 (0.0) |
 | Total | 152 (5.0) | 8 (0.5) | 9 (1.2) | </md>


[User] <|image|>Parse the diagram content behind with markdown code: <md> | Indication | Wesfleur (%) | Gugulethu (%) |

[Assistant]
| --- | --- | --- |
 | Myocardial infarction | 0.3 | 0 |
 | Valve replacement | 31 | 39 |
 | Mixed valve disease | 35 | 42 |
 | Atrial fibrillation | 47 | 39 |
 | Thrombosis/embolism | 24 | 6 | </md>


[User] <|image|>Convert the table into Markdown language.

[Assistant]
<md> |  | Costs (USD) | Incremental effects | Incremental cost-effectiveness |
 | --- | --- | --- | --- |
 | 80% MV wastage |  |  |  |
 | Restrictive MV policy | 54,420 | 0 | Reference |
 | MV-for-all policy | −1779 | 4223 discounted LYG | Cost-saving |
 | MV-for-all policy | −1779 | 160 deaths averted | Cost-saving |
 | 70% MV wastage |  |  |  |
 | Restrictive MV policy | 54,420 | 0 | Reference |
 | MV-for-all policy | −28,406 | 4223 discounted LYG | Cost-saving |
 | MV-for-all policy | −28,406 | 160 deaths averted | Cost-saving |
 | 33% reduction in mortality dueto MV as obtained from trial [11] |  |  |  |
 | Restrictive MV policy | 54,420 | 0 | Reference |
 | MV-for-all policy | 78,102 | 3029 discounted LYG | 7.8 USD/LYG |
 | MV-for-all policy | 78,102 | 115 deaths averted | 206 USD/death averted |
 | Lower confidence interval boundaryfrom WHO review (35%) [12] |  |  |  |
 | Restrictive MV policy | 54,420 | 0 | Reference |
 | MV-for-all policy | 78,102 | 3212 discounted LYG | 7.4 USD/LYG |
 | MV-for-all policy | 78,102 | 122 deaths averted | 194 USD/death averted |
 | Upper confidence interval boundaryfrom WHO review (55%) [12] |  |  |  |
 | Restrictive MV policy | 43,506 | 0 | Reference |
 | MV-for-all policy | 78,102 | 5050 discounted LYG | 4.7 USD/LYG |
 | MV-for-all policy | 78,102 | 192 deaths averted | 124 USD/death averted |
 | Using only costs incurred by the health system |  |  |  |
 | Restrictive MV policy | 25,497 | 0 | Reference |
 | MV-for-all policy | 91,413 | 4223 discounted LYG | 15.6 USD/LYG |
 | MV-for-all policy | 91,413 | 160 deaths averted | 412 USD/death averted | </md>


[User] <|image|>Express the picture as Markdown code.

[Assistant]
<md> | Item | Factor 1 – planning patient management | Factor 2 – patient education/involvement | Factor 3 – initial assessment | Factor 4 – physical examination planning |
 | --- | --- | --- | --- | --- |
 | Student asked the appropriate questions regarding patient’s history | 0.488 | 0.171 | 0.729 | 0.077 |
 | Student proposed the appropriate differential diagnoses | 0.396 | 0.276 | 0.772 | −0.051 |
 | Student proposed the appropriate clinical examination | 0.372 | 0.198 | 0.006 | 0.813 |
 | Student proposed the appropriate investigations | 0.760 | −0.027 | 0.226 | 0.290 |
 | Student proposed the appropriate referrals | 0.805 | 0.194 | 0.025 | 0.293 |
 | Student proposed the appropriate management | 0.795 | 0.161 | 0.196 | −0.153 |
 | Student explained the planned investigations and referrals to patient | −0.016 | 0.763 | 0.296 | 0.224 |
 | Student explained the planned management to patient | 0.149 | 0.879 | 0.107 | 0.101 |
 | Student explained the probable diagnosis to patient | 0.317 | 0.820 | −0.058 | −0.104 |
 | Student gave the patient instructions on self-management at home | 0.498 | 0.528 | −0.064 | −0.400 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Comparison | FI vs C | I vs C | F vs C | FI vs I | F vs I | F vs FI |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> 22 h |
 | Up-regulated | 1134 | 4 | 1010 | 1057 | 954 | 0 |
 | Down-regulated | 779 | 0 | 769 | 795 | 814 | 0 |
 | Ratio | 1.46 | na | 1.31 | 1.33 | 1.17 | na |
 | r | −0.43 | 0.89 | −0.38 | −0.39 | −0.38 | 0.90 |
 | <COLSPAN=7> 48 h |
 | Up-regulated | 1217 | 16 | 1230 | 1129 | 0 | 1200 |
 | Down-regulated |

[Assistant]
1068 | 10 | 1000 | 1047 | 1 | 1006 |
 | Ratio | 1.14 | 1.6 | 1.23 | 1.08 | 0 | 1.19 |
 | r | −0.55 | 0.86 | −0.55 | −0.48 | 0.90 | −0.51 |
 |  | 22 vs 48 h (FI) | 22 vs 48 h (I) | 22 vs 48 h (C) | 22 vs 48 h (F) |  |  |
 | Up-regulated | 45 | 30 | 0 | 7 |  |  |
 | Down-regulated | 25 | 32 | 8 | 11 |  |  |
 | Ratio | 1.8 | 0.94 | 0 | 0.64 |  |  |
 | r | 0.80 | 0.82 | 0.90 | 0.82 |  |  | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | <COLSPAN=2> Feature |
 | --- | --- |
 | Size (μm) | 3–6 |
 | Shape |

[Assistant]
Spherical or oval |
 | Number of buds | Single; chains |
 | Attachment of buds | Narrow |
 | Thickness | Thin |
 | Pseudohyphae &/or hyphae | Characteristic |
 | Number of nuclei | Single | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | <ROWSPAN=2>  | ErbB2 | ErbB2/IRS2 |
 | 25 Tumors-18 mice | 24 Tumors-17 mice |
 | --- | --- | --- |
 | <COLSPAN=3> Histological Types |
 | Solid Adenocarcinoma | 88 % (22/25) | 66 % (16/24) |
 | <COLSPAN=3> Differentiated |
 | Squamous Carcinoma | 0

[Assistant]
| 4 % (1/24) |
 | Adenosquamous Carcinoma | 8 % (2/25) | 21 % (5/24) |
 | Pillary | 0 | 4 % (1/24) | </md>


[User] <|image|>Convert the figure into Markdown language.

[Assistant]
<md> | Variable |  | No. | Percent (%) |
 | --- | --- | --- | --- |
 | Gender | male | 264 | 54.9 |
 |  | female | 217 | 35.1 |
 | Age | Mean (range), years | 40.79(1-81) |  |
 |  | <40 | 208 | 43.2 |
 |  | ≥40 | 273 | 56.8 |
 | Surgery | GTR | 328 | 68.2 |
 |  | NTR+STR | 153 | 31.8 |
 | Radiotherapy | GK | 315 | 62.5 |
 |  | CRT | 122 | 25.4 |
 |  | No | 44 | 9.1 |
 | Chemotherapy | Yes | 198 | 41.2 |
 |  | No | 283 | 58.8 |
 | WHO Grade | Grade I-II | 294 | 61.1 |
 |  | Grade III-IV | 187 | 38.9 |
 | Overall Survival | Median follow-up | 11 months |  |
 |  | Survival | 26 | 5.4 |
 |  | Loss to follow-up | 17 | 3.5 |
 |  | Death | 438 | 91.1 |
 | OS rate, % | 1 year | 31 |  |
 |  | 2 years | 10.3 |  |
 |  | 3 years | 7.5 |  |
 | Progression-free survival | Median follow-up | 8 months |  |
 |  | Progression-free | 24 | 5 |
 |  | Progression | 453 | 94.2 |
 |  | Total | 477 | 99.2 |
 |  | Missing System | 4 | 0.8 |
 | PFS rate, % | 1 year | 15.7 |  |
 |  | 2 years | 7.3 |  |
 |  | 3 years | 4.7 |  |
 |  | Total Number | 481 |  | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | Characteristics | 1999-2000 | 2001-2002 | 2003-2004 |
 | --- | --- | --- | --- |
 | Ages, mean (SE) | 56.4 (0.3) | 55.5 (0.4) | 56.3 (0.4) |

[Assistant]
| Non-Hispanic Blacks, % | 8.9 | 9.0 ↑ | 9.8 ↑↑ |
 | Diabetes, % | 8.6 | 9.1 ↑ | 10.7 ↑↑ |
 | Hypertension, % | 47.1 | 44.7 | 50.2 ↑ |
 | Hypercholesterolemia, % | 45.8 | 43.8 | 49.6 ↑ |
 | Smokers, % | 57.4 | 54.8 | 57.2 |
 | CHF, % | 2.9 | 2.6 | 3.2 | </md>


[User] <|image|>Convert the picture into Markdown language.

[Assistant]
<md> |  | M | SD | Proportion | 1 | 2 | 3 | 4 | 5 |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | (1) Perception of randomness | 3.90 | 1.06 | 77.19 |  |  |  |  |  |
 | (2) Base rate | 1.74 | 0.96 | 34.68 | 0.24∗∗ |  |  |  |  |
 | (3) Conjunction fallacy | 2.17 | 1.40 | 43.65 | 0.36∗∗ | 0.27∗∗ |  |  |  |
 | (4) Probability | 2.39 | 1.04 | 47.30 | 0.24∗∗ | 0.21∗∗ | 0.29∗∗ |  |  |
 | (5) Overall problem total | 10.21 | 3.03 | 50.70 | 0.67∗∗ | 0.60∗∗ | 0.77∗∗ | 0.63∗∗ |  | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Domain | Test/condition | <COLSPAN=4> RANCH | Emmen [29] |
 |  |  | Mean +/- Std | Min | Max | Median | Mean +/- Std |
 | Attention | Simple Reaction Time |  |  |  |  |  |
 | --- | --- | --- | --- | --- | --- | --- |
 |  | Latency (ms) | 357 +/- 51 | 256 | 572 | 350 | 303 +/- 57 |
 |  | Switching Attention |  |  |  |  |  |
 |  | Errors "block" (#) | 0.87 +/- 1.02 | 0 | 5 | 1 | 1 +/- 1.25 |
 |  | Reaction time "block" (ms) | 401 +/- 79 | 244 | 685 | 391 | 377 +/- 104 |
 |  | Errors "arrow" (#) | 1.71 +/- 1.59 | 0 | 8 | 1 | 1.25 +/- 1.36 |
 |  | Reaction time "arrow" (ms) |

[Assistant]
557 +/- 108 | 245 | 949 | 546 | 499 +/- 95 |
 |  | Errors "switch" (#) | 10.52 +/- 5.70 | 0 | 27 | 10 | 10.11 +/- 5.89 |
 |  | Reaction time "switch" (ms) | 693 +/- 147 | 247 | 1075 | 700 | 794 +/- 203 |
 | Locomotion | Hand Eye Coordination |  |  |  |  |  |
 |  | Deviation from sinus pattern (pixels) | 1.76 +/- 0.43 | 0.77 | 3.13 | 1.77 | 1.97 +/- 0.32 |
 | Perceptual Coding | Symbol Digit Substitution |  |  |  |  |  |
 |  | Latency (sec) | 3.31 +/- 0.56 | 2.11 | 5.95 | 3.23 | 3.28 +/- 0.71 |
 | Memory | Digit Memory Span |  |  |  |  |  |
 |  | Mean span-length forwards | 4.78 +-/0.63 | 3.30 | 7.60 | 4.70 | 4.9 +/- 0.7 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Variables | BA Patientswithout jaundice(n = 40) | BA Patients with Jaundice(n = 20) | P-value |
 | --- | --- | --- | --- |
 | Age (years) | 9.6 ± 0.9 | 9.5 ± 1.1 | 0.5 |
 | Gender (Female: Male) | 20:20 | 12:8 | 0.5 |
 | BMI (kg/m2) | 18.2 ± 0.6 | 17.1 ± 0.6 | 0.1 |
 | Albumin (g/dl) | 4.5 ± 0.1 | 3.9 ± 0.1 | <0.001 |
 | Total bilirubin (mg/dl) | 0.7 ± 0.1 | 6.5 ± 1.2 | <0.001 |
 | Direct bilirubin (mg/dl) | 0.4 ± 0.1 | 5.9 ± 1.2 | <0.001 |
 | AST (IU/l) | 98.3 ± 11.6 | 187.7 ± 18.2 | <0.001 |
 | ALT (IU/l) | 94.1 ± 9.7 | 140.3 ± 24.5 | 0.04 |
 | ALP (IU/l) | 369.8 ± 34.8 | 553.6 ± 33.9 | <0.001 |
 | Platelet count (103/mm3) | 183.5 ± 15.5 | 121.2 ± 19.9 | 0.01 |
 | APRI | 1.9 ± 0.4 | 5.0 ± 0.5 | <0.001 |
 | Adiponectin (μg/ml) | 11.0 ± 0.7 | 24.4 ± 1.4 | <0.001 |
 | Hyaluronic acid (ng/ml) | 28.9 ± 3.4 | 93.2 ± 16.7 | <0.001 |
 | Liver stiffness (kPa) | 18.5 ± 2.4 | 53.3 ± 4.3 | <0.001 | </md>


[User] <|image|>Encode the photo in Markdown syntax.

[Assistant]
<md> | Classes | HCS | VS |
 | --- | --- | --- |
 | Typical type (T) | LxxLxLxxNxL | xxLxxxxLxxLxx |
 | Bacterial type (S) | LxxLxLxxNxL | xxLPx(x)LPxx |
 | Ribonuclease inhibitor-like type (RI) | LxxLxLxxNxL | xxxxxxxLxxxLxxxxx |
 | SDS22-like type (SDS22) | LxxLxLxxNxL | xxLxxLxxLxx |
 | Cysteine-containing type (CC) | LxxLxLxxCxxL | TDxxxxxLxxxCxx |
 | Plant-specific type (PS) | LxxLxLxxNxL | xxxLPxxLGxLxx |
 | Treponema pallidum type (Tp) | LxxLxLPxxLxx | LxxxAFxxCxx |
 | CD42b type (CD42b) | LxxLxLxxNxL | xxLPxxxxxxxxx | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> |  | PB1 | PB2 | PB3 | PB4 | PB5 | PB6 | PB7 | PB8 |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | PB1 | 1 |  |  |  |  |  |  |  |
 | PB2 | 0.49 | 1 |  |  |  |  |  |  |
 | PB3 | −0.03 | −0.01 | 1 |  |  |  |  |  |
 | PB4 | 0.21 | 0.22 | 0.14 | 1 |  |  |  |  |
 | PB5 | 0.52 | 0.38 | −0.03 | 0.26 | 1 |  |  |  |
 | PB6 | 0.05 | 0.03 | 0.05 | 0.01 | 0.12 | 1 |  |  |
 | PB7 | 0.34 | 0.22 | −0.02 | 0.37 | 0.45 | 0.05 | 1 |  |
 | PB8 | 0.35 | 0.31 | 0.20 | 0.08 | 0.8 | 0.08 | 0.13 | 1 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | Cell type | pO2modulation | Cell differentiation/ mechanism | Ref. |
 | --- | --- | --- | --- |
 | BM-MSCs | CoCl2 | Dopaminergic neuron-like cells/HIF-1α dependent activation of EPO, VEGF, p21 | [115] |
 | Rat MSCs | Continuous hypoxia | Increased chondrogenesis/activation of HIF-1α, Akt, p38 MAPK, SOX-9 | [119] |
 | Human MSCs | Continuous hypoxia | Inhibited osteogenesis/ HIF-1α dependent inhibition of RUNX2 | [121] |
 |

[Assistant]
MSCs | Continuous hypoxia | Inhibited hypertrophic chondrogenesis | [122] |
 | BM-MSCs | Continuous hypoxia in alginate beads | Increased chondrogenesis/ HIF-1α dependent stimulation of SOX-9 | [123] |
 | Human BM-MSCs | Continuous hypoxia in gelatine hydrogel | Increased chondrogenesis | [124] |
 | Human ADSCc | Continuous hypoxia and chondrogenic medium | Increased chondrogenesis | [126] |
 | ADSCc | Continuous 2% oxygen tension | Decreased chondrogenesis and osteogenesis | [127] | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> | Districta | Arm | Hospitalb | Health centres | CHPS | Maternity home |
 | --- | --- | --- | --- | --- | --- |
 | District 1 | Intervention | 1 | 1 | 7 | 0 |
 | District 2 | Control | 2 | 6 | 10 | 1 |
 | District 3 | Intervention | 1 | 7 | 3 | 0 |
 | District 4 | Control | 1 | 5 | 4 | 1 |
 | District 5 | Intervention | 3 | 2 | 9 | 1 |
 | District 6 | Control | 1 | 6 | 7 | 0 |
 | District 7 | Intervention | 1 | 3 | 3 | 0 |
 | District 8 | Control | 3 | 4 | 6 | 2 |
 | District 9 | Control | 1 | 3 | 5 | 1 |
 | District 10 | Intervention | 3 | 2 | 0 | 1 |
 | District 11 | Intervention | 1 | 3 | 2 | 0 |
 | District 12 | Intervention | 1 | 8 | 1 | 1 |
 | District 13 | Control | 1 | 7 | 5 | 1 |
 | District 14 | Control | 3 | 6 | 1 | 0 |
 | District 15 | Control | 2 | 4 | 3 | 0 |
 | District 16 | Intervention | 1 | 3 | 3 | 1 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Article | Case | Gender | Age of onset |
 |  | number | (male/female ) | (male/female) |
 | --- | --- | --- | --- |
 | Lu H et al. [4] | 1 | 1/0 | 66/ |
 | Wang Y et al. [5] | 1 | 0/1 | /77 |
 | Gai QW et al. [6] | 2 | 2/0 | 69,67/ |
 | Yang GE et al. [7] | 1 | 1/0 | 50/ |
 | Chen L et

[Assistant]
al. [8] | 8 | 6/2 | 63 ~ 72 |
 | Zhang XQ et al. [9] | 1 | 0/1 | /63 |
 | Wu XP [10] | 4 | 2/2 | 68,66/58, unknown |
 | Yang WM [11] | 3 | 3/0 | 56,56,75/ |
 | Li YM et al. [12] | 1 | 1/0 | 70/ |
 | Wang EZ [13] | 1 | 0/1 | /40 |
 | Xian HT [14] | 2 | 2/0 | 68,75/ |
 | W R et al. [15] | 1 | 0/1 | /74 |
 | Li JL et al. [16] | 1 | 1/0 | 72/ |
 | Liu XS et al. [17] | 4 | 4/0 | 71,74,76,77/ |
 | Wang XH et al. [18] | 1 | 1/0 | 53/ |
 | Fu YH et al. [19] | 1 | 0/1 | /81 |
 | Yang L et al. [20] | 1 | 1/0 | 70/ |
 | Lu WF et al. [21] | 1 | 1/0 | 76/ | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | <COLSPAN=2> Groups n (%) | Gestational age (weeks)X ± SD | Perinatal weight (grams)X ± SD | EW (grams) | P♦ |
 | --- | --- | --- | --- | --- | --- |
 | Perinatal anoxia | 21 (43.75) | 32.4 ± 5.4 | 2110.48 ± 966.01 | 1488 | <0.05 |
 | Ascending infection | 15 (31.25) | 31.3 ± 5.9 | 1828.73 ± 1035.47 | 1359 | <0.05 |
 | Congenital malformation | 12 (25.00) | 33.5 ± 2.4 | 2225.00 ± 1149.84 | 1663 | <0.05 |
 | Total | 48 (100.00) |  |  |  |  | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | n = 50 gated patients | No Fibrosis/infarction by CMR | Fibrosis/infarction by CMR |
 | --- | --- | --- |

[Assistant]
 | Normal function by gated SPECT | 36 | 3 |
 | Abnormal function by gated SPECT | 7 | 4 | </md>


[User] <|image|>Convert the picture to Markdown syntax.

[Assistant]
<md> | Group | Size (nm) | Polydispersion | Zeta potential (mV) | Loading efficiency (%) | Gene | Polymer |
 |  | (n = 3) |  | (n = 3) | (n = 3) |  |  |
 | --- | --- | --- | --- | --- | --- | --- |
 | ANP | 72.11 ± 3.44 | 0.164 | 22.54 ± 3.47 | 83.4 ± 2.3 | TRAIL | PEI |
 | BNP | 71.82 ± 5.18 | 0.156 | 21.58 ± 4.16 | 82.6 ± 1.9 | Endostatin | PEI |
 | CNP | 83.02 ± 2.35 | 0.178 | 24.65 ± 2.78 | 78.3 ± 3.8 | TRAIL/endostatin | PEI |
 | DNP | 215.06 ± 3.52 | 0.186 | −18.25 ± 2.36 | 0 | None | TPGS-b-(PCL-ran-PGA) |
 | ENP | 236.31 ± 1.44 | 0.201 | 23.65 ± 3.65 | 0 | None | PEI/TPGS-b-(PCL-ran-PGA) |
 | FNP | 265.48 ± 4.40 | 0.229 | 19.45 ± 1.99 | 67.4 ± 4.3 | TRAIL | PEI/TPGS-b-(PCL-ran-PGA) |
 | GNP | 245.48 ± 6.42 | 0.215 | 18.45 ± 2.67 | 64.6 ± 3.1 | Endostatin | PEI/TPGS-b-(PCL-ran-PGA) |
 | HNP | 272.97 ± 4.68 | 0.245 | 16.54 ± 1.06 | 62.5 ± 0.9 | TRAIL/endostatin | PEI/TPGS-b-(PCL-ran-PGA) | </md>


[User] <|image|>Interpret the photo as Markdown format.

[Assistant]
<md> | <ROWSPAN=3-COLSPAN=2>  | <COLSPAN=4> qPCRa |
 | <COLSPAN=2> P. falciparum | <COLSPAN=2> P. vivax |
 | Positive | Negative | Positive | Negative |
 | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> RT-qPCR | Positive | 42 | 1 | 18 | 1 |
 | Negative | 0 | 35 | 0 | 59 |
 | <COLSPAN=6>  |
 | <COLSPAN=2>  | P. falciparum (%) | 95% CI | P. vivax (%) | 95% CI |
 | <COLSPAN=2> Sensitivity | 100 | 91.59–100 | 100 | 81.47–100 |
 | <COLSPAN=2> Specificity | 97.20 | 85.47–99.93 | 98.33 | 91.06–99.96 | </md>


[User] <|image|>Transform the picture into Markdown format.

[Assistant]
<md> | Dates (2010) | Weeks (2010) | Activities |
 | --- | --- | --- |
 | January 20 to February 1 | 3 to 4 | Preparation: |
 |  |  | ▪ Cartography and listing of sites to prepare sampling frame |
 |  |  | ▪ Division into strata and selection of sentinel sites |
 |  |  | ▪ Development and adaptation of procedures and registers |
 | February 2 to March 7 | 5 to 9 | Stepwise implementation (about two strata per week): |
 |  |  | ▪ Identification of staff |
 |  |  | ▪ Visit to sentinel sites |
 |  |  | ▪ Three-day training and pilot |
 |  |  | ▪ Baseline census during first week, then weekly household visits for demographic and nutritional data collection |
 | March 8 | 10 | Weekly household visits started in all sentinel sites |
 | July 12 to 18 | 28 | Repeat census |
 | October 3 | 39 | End of nutritional data collection |
 | October 3 to 14 | 39 to 40 | Evaluation visit |
 |  |  | ▪ Capture-recapture study for mortality accuracy assessment (analyzed deaths during weeks 31 to 38) |
 |  |  | ▪ Review of paper registers |
 | December 31 | 52 | End of demographic data collection | </md>


[User] <|image|>Interpret the illustration as Markdown format.

[Assistant]
<md> | Variables | Patients without potential drug-drug interactions in their prescriptionn = 132 | Patients with at least one potential drug-drug interactions in their prescriptionn = 492 |
 | --- | --- | --- |
 | Gender (female) | 105 (79.5) | 386 (78.5) |
 | Civil status (single) | 61 (46.2) | 259 (52.6) |
 | Did not work | 102 (77.3) | 416 (84.6) |
 | Literacy (only elementary school o less) | 67 (54.9) | 266 (62.9) |
 | Patient age ≥ 60* | 87 (65.9) | 406 (82.5) |
 | Number of disease ≥ 3* | 73 (55.3) | 396 (80.5) |
 | Cardiovascular disease* | 43 (32.6) | 403 (81.9) |
 | Musculoskeletal and joint disorders | 126 (95.5) | 471(95.7) |
 | Gastrointestinal disease | 48 (36.4) | 205 (41.7) |
 | Endocrine, alimentary and metabolic disease* | 38 (28.8) | 275 (55.9) |
 | Pulmonary disease | 8 (6.0) | 31 (6.3) |
 | Mental disease | 12 (9.1) | 21 (4.3) |
 | Neurological disease | 11 (8.3) | 40 (8.1) |
 | Infections and parasitic disease | 30 (22.7) | 88 (17.9) |
 | Number of medicines ≥ 5* | 50 (37.9) | 383 (77.8) | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> | Time | <ROWSPAN=2> 0–4 h | <ROWSPAN=2> 4–8 h | <ROWSPAN=2> 8–12 h | <ROWSPAN=2> 12–24 h | <ROWSPAN=2> 72 h | <ROWSPAN=2> 120 h |
 | Groups |
 | --- | --- | --- | --- | --- | --- | --- |
 | Infected | 4.16 ± 0.14 | 5.46 ± 0.07 | 4.57 ± 0.06 | 4.47 ± 0.1 | 5.34 ± 0.14 | 6.57 ± 0.15 |
 | C | 4.25 ± 0.15 | 4.86 ± 0.19 | 3.64 ± 0.3 | 3.07 ± 0.005 | 2.57 ± 0.2# | 0#^ |
 | P | 4.27 ± 0.18 | 4.34 ± 0.25 | 4.21 ± 0.31 | 4.12 ± 0.17 | 3.5 ± 0.46 | 3.36 ± 0.25#@ |
 | CP1 | 4.34 ± 0.15 | 4.5 ± 0.19 | 4.1 ± 0.30 | 3.36 ± 0.005 | 3.51 ± 0.2 | 2.15 ± 0#@ |
 | CP2 | 4.57 ± 0.11 | 4.34 ± 0.26 | 4.21 ± 0.18 | 4.12 ± 0.48 | 3.5 ± 0.19 | 3.12 ± 0.18#@ |
 | CP3 | 4.27 ± 0.18 | 4.34 ± 0.25 | 4.21 ± 0.31 | 4.12 ± 0.17 | 3.5 ± 0.46 | 3.36 ± 0.25#@ |
 | CP4 | 4.54 ± 0.06 | 5.53 ± 0.39 | 5.86 ± 0.17 | 5.47 ± 0.19 | 4.34 ± 0.06 | 4.24 ± 0.13@ | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | <COLSPAN=2> ELM | <COLSPAN=2> Sequences |
 | --- | --- | --- | --- |
 | Functional class | GO category | PDB id | GO category |
 | LIG_14-3-3_2 | Binding | 2O34A, 2FPHX, 1NAR0, 2DDXA | Binding, catalytic activity |
 | LIG_PP1 | Binding, enzyme regulator activity | 2HHPA, 2HFKA, 1D3YA, 1OI7A, 1ZY7A, 2B18A, 2F2HA, 2GZQA | Binding, catalytic activity, transporter activity, transcription regulator activity |
 | LIG_PP2B_1 | Binding, catalytic activity | 1ES5A, 1T8TA, 1EZWA, 1V5VA | Catalytic

[Assistant]
activity |
 | LIG_MAPK_1 | Binding | 1B43A, 1NSZA, 2GAKA, 2O34A, 1VPDA, 2NQTA | Binding, catalytic activity, |
 | LIG_SCF-TrCP1_1 | Binding, catalytic activity | 1B43A, 1Y8TA, 1M4LA, 2IDLA | Binding, catalytic activity |
 | LIG_14-3-3_3 | Binding | 2IDLA, 2HHPA, 2O34A, 1UG6A, 2C0HA, 1B12A, 1O54A, 2FPHX, 1GNLA, 2FMPA, 1D3GA, 2ES4D, 2DXQA, 2A67A, 2G0WA, 1PO5A, 1Q74A, 1CNV0, 1JNDA, 1KMVA, 2JG0A, 7A3HA | Binding, catalytic activity |
 | LIG_EH1_1 | Binding | 1B12A, 2C0HA, 1WDPA, 2CK3H, 1O54A, 2HHPA, 1R5YA, 2D0OA, 1USGA, 2DG1A, 1O2DA, 1YACA, 1RYIA, 1VZIA, 1NAR0, 2DSKA, 1NTHA, 2AFWA, 2C61A, 1D3GA, 1NNWA, 2NX9A, 1X13A, 2A67A, 1C8XA, 2AEEA, 1YDYA, 2GAKA | Binding, catalytic activity |
 | LIG_BRCT_BRCA1_1 | Binding | 1FSGA, 1OQ1A, 2FPQA, 1ZMTA, 2AZ4A, 1NOFA, 1UEKA, 2HSIA | Binding, catalytic activity |
 | LIG_NRBOX | Binding | 1M4LA, 2NT0A, 2NX9A, 1VLRA, 2DJFA, 1DQPA, 1G2QA, 1J2RA, 1NF9A, 1ITXA, 2JE8A, 1B25A, 1CNV0, 1NAR0, 2DSKA, 2CK3H, 2IACA, 1FSGA, 1VJPA, 1NTHA, 2HSIA | Binding, catalytic activity |
 | LIG_CORNRBOX | Binding | 1O54A, 2C61A, 1C8XA, 1LBVA | Binding, catalytic activity, transporter activity | </md>


[User] <|image|>Encode the illustration in Markdown syntax.

[Assistant]
<md> | <ROWSPAN=3> Age group | <COLSPAN=2> Noun comprehension mean | <COLSPAN=2> Predicate comprehension mean |
 | n | SD | n | SD |
 | --- | --- | --- | --- | --- |
 | Group 25-months | 13.75 | 2.2 | 11.75 | 3.2 |
 | Group 30-months | 14.67 | 1.6 | 12.58 | 2.8 |
 | Group 36-months | 16.08 | 2.5 | 13.33 | 2.4 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Fetal outcome | Percentage |
 | --- | ---

[Assistant]
|
 | Pre term | 12.8% |
 | Still birth | 2.5% |
 | Full term live birth | 84.6% | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Combinationa | <COLSPAN=2> FICI in: |
 | RPMI | MHB |
 | --- | --- | --- |
 | CRO+CIP | 0.3125 | 0.50 |
 | CRO+AZM | 0.50 | NAb |
 | CIP+AZM | 1 | NA |
 | CRO+LL-37 | 0.5 | NA |
 | CIP+LL-37 | 0.5 | NA |
 | AZM+LL-37 | 0.75 | NA |
 | CM+LL-37 | 1 | NA | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Individual ID | Transcript ID | Set ID |
 | --- | --- | --- |
 | NA20805 | NM_001163941.1 | 7619 |
 | NA20805 |

[Assistant]
NM_001163942.1 | 3062 |
 | NA20805 | NM_001163993.2 | 3062 |
 | NA20805 | NM_178559.5 | 7619 |
 | NA20806 | NM_178559.5 | 2807 |
 | NA20806 | NM_001163993.2 | 3062 |
 | NA20806 | NM_001163942.1 | 3062 |
 | NA20806 | NM_001163941.1 | 2807 |
 | ... | ... | ... | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | GO Biological Process | GO Accession | Number of genes | Pvalue (FDR adjusted) | D |
 | --- | --- | --- | --- | --- |
 | RNA splicing | GO:0008380 | 122 | 5.73E-04 | 0.21 |
 | DNA repair | GO:0006281 | 116 | 5.73E-04 | 0.17 |
 | Protein modification by small protein conjugation | GO:0032446 | 122 | 5.73E-04 | 0.17 |
 | Viral reproduction | GO:0016032 | 140 | 5.73E-04 | 0.15 |
 | mRNA processing | GO:0006397 | 163 | 1.13E-03 | 0.18 |
 | Interphase of mitotic cell cycle | GO:0051329 | 170 | 1.13E-03 | 0.16 |
 | Protein catabolic process | GO:0030163 | 196 |

[Assistant]
1.86E-03 | 0.15 |
 | Interphase | GO:0051325 | 172 | 1.86E-03 | 0.15 |
 | RNA splicing, via transesterification reactions | GO:0000375 | 83 | 2.31E-03 | 0.22 |
 | Protein ubiquitination | GO:0016567 | 119 | 2.76E-03 | 0.15 |
 | Translation | GO:0006412 | 101 | 3.53E-03 | 0.16 |
 | rRNA metabolic process | GO:0016072 | 30 | 7.11E-03 | 0.33 |
 | Chromatin modification | GO:0016568 | 97 | 7.11E-03 | 0.15 |
 | M phase | GO:0000279 | 165 | 7.84E-03 | 0.13 |
 | Cellular protein catabolic process | GO:0044257 | 164 | 8.92E-03 | 0.14 |
 | rRNA processing | GO:0006364 | 28 | 9.76E-03 | 0.33 | </md>


[User] <|image|>Translate the picture into Markdown format.

[Assistant]
<md> | Subject: | <COLSPAN=3> End-diastolic volume (mL) | <COLSPAN=3> End-systolic volume (mL) | <COLSPAN=3> Ejection fraction (%) |
 |  | All | Non-Ectopic | Ectopic | All | Non-Ectopic | Ectopic | All | Non-Ectopic | Ectopic |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1 | 197.5 ± 8.4 | 231.4 ± 9.9 | 165.6 ± 7.3 | 95.1 ± 4.4 | 84.4 ± 4.4 | 106.6 ± 4.5 | 51.9 ± 4.3 | 63.5 ± 9.2 | 35.7 ± 9.6 |
 | 2 | 133.9 ± 5.7 | 149.4 ± 5.9 | 114.8 ± 5.2 | 76.3 ± 4.2 | 69.7 ± 3.8 | 84.9 ± 5.1 | 43.0 ± 11.4 | 53.3 ± 8.4 | 26.0 ± 14.9 |
 | 3 | 113.8 ± 6.9 | 128.3 ± 7.6 | 88.7 ± 6.2 | 56.4 ± 4.6 | 57.9 ± 4.7 | 54.9 ± 4.5 | 50.5 ± 8.8 | 54.9 ± 8.2 | 38.2 ± 13.5 |
 | 4 | 123.0 ± 6.7 | 130.3 ± 7.3 | 104.1 ± 5.8 | 43.1 ± 4.1 | 44.9 ± 4.5 | 42.1 ± 2.4 | 65.0 ± 12.2 | 65.5 ± 13.4 | 59.6 ± 9.6 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Component | g/kg-biomass |
 | --- | --- |
 | Cellulose | 395 |
 | Hemicellulose | 293 |
 | Lignin | 230 |
 | Wax | 40 |
 | Ash

[Assistant]
| 45 |
 |  | g-sugar/kg-biomass |
 | Glucose | 436 |
 | Xylose | 192 |
 | Arabinose | 28 |
 | Mannose | 7 |
 | Galactose | 8 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Player type | Difference in training accuracy | Difference in testing accuracy |
 | --- | --- | --- |
 | AllC | 0.001 | 0.001 |
 | TFT | 0.061 | 0.150 |
 | NoisyTFT | 0.018 | 0.123 |
 | Major | −0.014 | −0.081 |
 | Major 5 | 0.019 | 0.101 |
 | Pavlovian | 0.042 | 0.205 | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | <COLSPAN=5> Number of studies including most commonly used adjuvants/immunostimulants |
 | Adjuvant | Phase 2 | Phase 2/3 | Phase 3 | Total |
 | --- | --- | --- | --- | --- |
 | GM-CSF | 92 | 1 | 16 | 109 |
 | Montanide | 60 | 1 | 5 | 66 |
 | IL-2 | 53 |  | 3 | 56 |
 | KLH | 16 |  | 8 | 24 |
 | TRICOM | 10 |  | 3 | 13 |
 | QS21 | 5 |  | 1 | 6 |
 | Poly-ICLC | 8 | 0 | 0 | 8 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Groups | 0 Day | 3 Days | 6 Days | 9 Days | 12 Days | 15 Days |
 | --- | --- | --- | --- | --- | --- | --- |
 | NC | 174.2 ± 6.5 | 176.5 ± 4.23 | 178.4 ± 2.25 | 180.2 ± 4.32 | 183.8 ± 3.56 | 186.4 ± 5.78 |
 | DC | 166.4 ± 3.9 | 167.4 ± 4.0 | 168.6 ± 4.2 | 170.4 ± 3.7 | 174.8 ± 3.8 | 175.0 ± 4.4 |
 | DS | 156.6 ± 4.5 | 157.6 ± 4.2 | 157.8 ± 4.4 | 159.4 ± 5.7 | 163.1 ± 4.5 | 157.4 ± 3.2 |
 | SA 100 | 156.6 ± 4.4 | 152.8 ± 5.3 | 150.8 ± 7.5 | 150.4 ± 8.3 | 147.8 ± 9.4 | 146.2 ± 9.5 |
 | SA 200 | 153.4 ± 5.6 | 153.75 ± 4.6 | 154.51 ± 8.5 | 156.7 ± 3.3 | 163.5 ± 5.6 | 166.6 ± 6.0 |
 | SA 400 | 157.2 ± 6.5 | 158.2 ± 7.5 | 159.5 ± 5.3 | 161.5 ± 6.8 | 170.6 ± 3.4 | 172.4 ± 3.7 | </md>


[User] <|image|>Express the table as Markdown code.

[Assistant]
<md> | Virus | Clade | VRC07 IgG | VRC07 Fab | VRC07-αCD3 |
 | --- | --- | --- | --- | --- |
 | Q23.17.SG3 | A | 0.036 | 0.056 | 0.025 |
 | AC10.29.SG3 | B | 0.114 | 0.576 | 0.346 |
 | ZM53.12.SG3 | C | 0.217 | 0.524 | 0.240 | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | Ingredientes | Control (g/kg) | N-60 a (g/kg) | N-200 a (g/kg) | N-400 a (g/kg) | N-600 a (g/kg) |
 | --- | --- | --- | --- | --- | --- |
 | Corn starch | 530 | 517 | 519 | 520 | 521 |
 | Sucrose | 100 | 100 | 100 | 100 | 100 |
 | Casein b | 200 | 177 | 193 | 195.6 | 195 |
 | Soybean oil | 70 | 63.9 | 66 | 68 | 67.5 |
 | Fiber c | 50 | 30 | 36.8 | 37 | 38 |
 | MixMin d | 49 | 34 | 42 | 44 | 43 |
 | Mix Vit e | 10 | 10 | 10 | 10 | 10 |
 | L-Cystein | 3 | 3 | 3 | 3 | 3 |
 | Choline bitartarate | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 |
 | CaCO3f | 12.5 | - | - | - | - |
 | O. ficus indicag | - | 280 | 168 | 140 | 132 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Time | <COLSPAN=2> Act v Man | <COLSPAN=2> Act v Mob | <COLSPAN=2> Man v Mob |
 |  | Mean | 95% CI | Mean | 95% CI | Mean | 95% CI |
 | --- | --- | --- | --- | --- | --- | --- |
 | End | 2.39 | -3.79 to 8.57 | 1.67 | -6.14 to 9.47 | -0.73 | -7.93 to 6.48 |
 | 3 | 1.56 | -4.01 to 7.12 | -2.56 | -10.73 to 5.61 | -4.11 | -11.59 to 3.36 |
 | 6 | -2.72 | -10.04 to 4.59 | -3.68 | -12.81 to 5.46 | -0.95 | -9.55 to

[Assistant]
7.64 |
 | 12 | -4.41 | -12.48 to 3.66 | -4.53 | -13.87 to 4.80 | -0.12 | -8.64 to 8.39 | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Risk factors | Categories | N | HPV+ | % | Adj. OR | LL–UL | P value |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <ROWSPAN=5> Age at sample collection (years) | <30* | 56 | 3 | 5.36 | . | . | . |
 | 30-39 | 124 | 12 | 9.68 | 3.310 | 0.391–28.052 | 0.2723 |
 | 40-49 | 132 | 12 | 9.09 | 2.097 | 0.230–19.085 | 0.5110 |
 | 50-60 | 89 | 12 | 13.48 | 4.136 | 0.454–37.681 | 0.2079 |
 | >60 | 14 | 2 | 14.29 | 9.570 | 0.601–152.366 | 0.1097 |
 | <ROWSPAN=2> Nationality | Non-Saudi* | 96 | 16 | 16.67 | . | . | . |
 | Saudi | 321 | 25 | 7.79 | 0.315 | 0.116–0.855 | 0.0234 |
 | <ROWSPAN=4> Education level | No formal education* | 21 | 2 | 9.52 | . | . | . |
 | Primary | 47 | 3 | 6.38 | 1.039 | 0.144–7.489 | 0.9693 |
 | Secondary | 50 | 4 | 8.00 | 1.515 | 0.200–11.492 | 0.6879 |
 | Post-secondary/University | 201 | 24 | 11.94 | 1.158 | 0.180–7.447 | 0.8770 |
 | <ROWSPAN=2> Number of marital partners | 1* | 286 | 29 | 10.14 | . | . | . |

[Assistant]
 | 2-5 | 32 | 4 | 12.50 | 1.129 | 0.324–3.941 | 0.8488 |
 | <ROWSPAN=4> Parity | 0* | 8 | 0 | 0.00 | . | . | . |
 | 1-2 | 100 | 11 | 11.00 | >999.999 | <0.001– > 999.999 | 0.9516 |
 | 3-5 | 112 | 14 | 12.50 | >999.999 | <0.001– > 999.999 | 0.9502 |
 | ≥ 6 | 71 | 5 | 7.04 | >999.999 | <0.001– > 999.999 | 0.9518 |
 | <ROWSPAN=2> Smoking status | No* | 273 | 30 | 10.99 | . | . | . |
 | Yes | 44 | 3 | 6.82 | 0.502 | 0.134–1.875 | 0.3053 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | Years | Malaria suspected cases | Investigated for malaria | % | Malaria cases (confirmed + clinical)a | % | Confirmed malaria cases | % | Clinical malaria cases | % |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 2012 (1) | 71,800 | 62,455 | 87.0 | 26,817 | 37.3 | 24,698 | 92.1 | 2119 | 7.9 |
 | 2013 (2) | 292,986 | 288,225 | 98.4 | 89,985 | 30.7 | 84,080 | 93.4 | 5905 | 6.6 |
 | 2014 (3) | 336,250 | 328,760 | 97.8 | 74,566 | 22.2 | 73,673 | 98.8 | 893 | 1.2 |
 | 2015 (4) | 172,671 | 172,554 | 99.9 | 31,925 | 18.5 | 31,808 | 99.6 | 117 | 0.4 |
 | Grand total | 873,707 | 851,994 | 97.5 | 223,293 | 25.6 | 214,259 | 96.0 | 9034 | 4.0 | </md>


[User] <|image|>Express the diagram as Markdown code.

[Assistant]
<md> | <COLSPAN=2>  | <COLSPAN=3> Diseased fold-change1 |
 | Description | General function | Accession | Lung | Skin |
 | --- | --- | --- | --- | --- |
 | Calprotectin | Innate immunity | F6QJD8 | +255 | + |
 | 78 kDa glucose-regulated protein | Adaptive immunity | F7C3R1 | +14 | + |
 | Alpha-1-acid glycoprotein 1 | Acute phase protein | G7PRL2 | + | +10 |
 | Alpha-1-antichymotrypsin | Acute phase protein | F6SL79 | + | +8 |
 | C3 and PZP-like alpha-2- macroglobulin domain-containing protein 1 | Inflammation induced | G7PYU9 | +20 | +256 |
 | Calreticulin (CRP55) | Calcium homeostasis | F7FMQ2 | +67 | + |
 | Endoplasmin | Immune chaperone | F7EZT6 | +10 | +256 |
 | Erythrocyte band 7 integral membrane protein isoform a | Red blood cell protein | F7HP19 | +255 | + |
 | Fibrinogen alpha chain | Clotting | F6UZ60 | +25 | +203 |
 | Hemoglobin alpha chain | Red blood cell protein | G7Q017 | −20 | +12 |
 | Hemoglobin subunit beta | Red blood cell protein | F7APQ4 | +3 | + |
 | Leukocyte elastase inhibitor | Innate immunity | G7P4B6 | +27 | + |
 | Purine nucleoside phosphorylase (Fragment) | Purine metabolism | G8F5P6 | +10 | + |
 | Scinderin | Secretory pathway | F6T8Z7 | + | + |
 | Serum amyloid A protein | Acute phase protein | F7DY68 | +63 | +4 |
 | Superoxide dismutase [Mn] mitochondrial | Innate immunity | Q8HXP2 | +75 | +26 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | <ROWSPAN=3> Monitoring regions | <ROWSPAN=3> % Correct | <COLSPAN=2> Season assigned DA | <ROWSPAN=3> Monitoring regions | <ROWSPAN=3> % Correct | <COLSPAN=2> Season assigned DA |
 | <COLSPAN=2> Kowalskie | <COLSPAN=2> Stare Miasto |
 | K-1 | K-2 | S-1 | S-2 |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=8> Standard DA mode |
 | K-1 | 95.00 | 19 | 1 | S-1 | 80.56 | 29 | 7 |
 | K-2 | 97.06 | 1 | 33 | S-2 | 83.336 | 6 | 30 |
 | Total | 96.30 | 20 | 34 | Total | 81.946 | 35 | 37 |
 | <COLSPAN=8> Forward stepwise DA mode |
 | K-1 | 95.00 | 19 | 1 | S-1 | 86.12 | 31 | 5 |
 | K-2 | 97.06 | 1 | 33 | S-2 | 83.34 | 6

[Assistant]
| 30 |
 | Total | 96.30 | 20 | 34 | Total | 84.73 | 37 | 35 |
 | <COLSPAN=8> Back ward stepwise DA mode |
 | K-1 | 65.00 | 13 | 7 | S-1 | 63.89 | 23 | 13 |
 | K-2 | 85.29 | 5 | 29 | S-2 | 86.11 | 5 | 31 |
 | Total | 77.78 | 18 | 36 | Total | 75.00 | 28 | 44 | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=2> Holter-ECG at 6 months |  |
 | AF (n = 17) (mean ± SD) | NSR (n = 59) (mean ± SD) | Test statistics |
 | --- | --- | --- | --- |
 | LA | 5.11 ± 0.74 | 4.98 ± 0.63 | z: –0.422; p: 0.673 |
 | LVEDD | 4.75 ± 1.30 | 5.06 ± 0.70 | t: –1,192; p: 0.238 |
 | LVESD | 3.38 ± 0.78 | 3.25 ± 0.81 | t: 0.534; p: 0.596 |
 | EF | 55.12 ± 9.79 | 55.07 ± 9.46 | t: 0.017; p: 0.987 |
 | PAP | 50.56 ± 14.16 | 46.70 ± 12.22 | t: 1.036; p: 0.304 |
 | LVEDP | 9.00 ± 5.24 | 10.77 ± 11.77 | t: –0.557; p: 0.580 |
 | MAXG* | 18.75 ± 2.81 | 17.43 ± 5.59 | t: 0.633; p: 0.532 |
 | MVA* | 1.55 ± 0.92 | 1.20 ± 0.81 | z: –0.773; p: 0.440 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Parameter | RA group (n = 82) | Control group (n = 87) | p value |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Sex of subjects, n (% of group) |
 | Female | 61 (74.4%) | 50 (57.5%) | <ROWSPAN=2> 0.0012 |
 | Male | 21 (25.6%) | 37 (42.5%) |
 | Age (years), median (range) | 54 (20–82) | 53 (25–78) | NS |
 | <COLSPAN=4> BMI (kg/m2), n (%) |
 | <18.5 | 2 (2.4%) | 2 (2.3%) | <ROWSPAN=3> NS |
 | 18.5–24.9 | 36 (43.9%) | 29 (33.3%) |
 | ≥25

[Assistant]
| 44 (53.7%) | 56 (64.4%) |
 | <COLSPAN=4> Cigarette smoking, n (%) |
 | Current smoker | 22 (26.8%) | 31 (35.6%) | <ROWSPAN=3> 0.023 |
 | Former smoker (cessation ≥ 1 year) | 29 (35.4%) | 38 (43.7%) |
 | Never smoker | 31 (37.8%) | 18 (20.7%) |
 | Albumin (g/dL), median (range) | 3.93 (2.57–5.70) | 4.23 (2.85–5.42) | <0.000001 |
 | Uric acid (g/dL), median (range) | 4.3 (1.5–9.1) | 5.2 (3.0–8.8) | NS |
 | Time from RA onset (years), median (range) | 8.5 (0.2–50) | — | — |
 | RF + (cutoff 20 IU/mL), n (%) | 53 (64.6%) | — | — |
 | ACPA + (cutoff 25 U/mL), n (%) | 41 (50.0%) | — | — |
 | Number of swollen joints, median (range) | 4 (0–24) | — | — |
 | DAS 28, median (range) | 5.01 (1.49–8.49) | — | — |
 | Treatment |  |  | — |
 | Methotrexate | 46 (56.1%) | — | — |
 | Other nonbiologic DMARDs | 33 (40.2%) | — | — |
 | Anti-TNF therapy | 23 (28.0%) | — | — |
 | Steroids | 62 (75.6%) | — | — | </md>


[User] <|image|>Interpret the photo as Markdown format.

[Assistant]
<md> | Township | Population ( <5 yo) | BCG | Pentavalent | OPV | MMR | DPT |
 | --- | --- | --- | --- | --- | --- | --- |
 | Calucica | 77 | 100.00% | 98.70% | 97.40% | 96.10% | 90.91% |
 | Colomarigua o El Tablón | 74 | 100.00% | 94.59% | 97.30% | 98.65% | 97.30% |
 | Concepción | 159 | 99.37% | 99.37% | 100.00% | 99.37% | 94.97% |
 | El Guachipilincito | 81 | 98.77% | 96.30% | 96.30% | 97.53% | 95.06% |
 | El Guajiniquil | 133 | 99.25% | 98.50% | 97.74% | 99.25% | 96.99% |
 | El Rodeo | 87 | 98.85% | 86.21% | 93.10% | 97.70% | 96.55% |
 | Jiquinlaca | 276 | 97.46% | 96.38% | 95.65% | 98.91% | 93.48% |
 | San Nicolás | 111 | 98.20% | 98.20% | 98.20% | 100.00% | 97.30% |
 | Santiago | 146 | 100.00% | 96.58% | 97.26% | 98.63% | 93.15% |
 | Total | 1144 | 98.86% | 96.50% | 97.03% | 98.69% | 94.84% | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> |  | <COLSPAN=4> MLP classification result |
 |  | Negative | CIN1 | CIN2/3 | Ca |
 | --- | --- | --- | --- | --- |
 | Histological examination result |  |  |  |  |
 | Negative/clinically negative | 11 | 1 | 0 | 0 |
 | CIN1 | 4 | 8 | 0 | 0 |
 | CIN2/3 | 0 | 1 | 1 | 0 |
 | SCC/Adeno-Ca | 0 | 0 | 0 | 0 | </md>


[User] <|image|>Express the figure as Markdown code.

[Assistant]
<md> |  | All | Patients/concord affected pairs |
 | --- | --- | --- |
 | Total | 315 | 74 |
 | Male | 169 | 43 |
 | Female | 146 | 31 |
 | Parent-offspring | 443 | 65 |
 | Sib-sib | 317 | 73 |
 | Sister-sister | 101 | 12 |
 | Brother-brother | 74 | 32 |
 | Sister-brother | 142 | 32 |
 | Grandparental | 340 | 13 |
 | Avuncular | 840 | 38 |
 | Cousin | 811 | 54 | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | Groups | MDA (nmole/mg of protein) | NO (nmole/mg of protein) | SOD (U/min/mg of protein) | Mast cell degranulation (% protection) |
 | --- | --- | --- | --- | --- |
 | Control | 17 ± 0.7 | 12 ± 0.5 | 0.89 ± 0.05 | 80 ± 1.5 |
 | Model | 88 ± 2.1* | 28 ± 1.1* | 0.22 ± 0.03* | 8 ± 0.5* |
 | Prednisolone | 34 ± 1.4# | 14 ± 0.8# | 0.78 ± 0.05# | 62 ± 1.0# |
 | AEFB (250 mg/kg) | 50 ± 1.7# | 20 ± 0.5# | 0.7 ± 0.02# | 45 ±

[Assistant]
0.8# |
 | AEFB (500 mg/kg) | 38 ± 1.8# | 16 ± 0.6# | 0.62 ± 0.03# | 54 ± 0.9# | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | <ROWSPAN=2> Confidence | <COLSPAN=3> Adolescents, No. (%)a |
 | All Ages | Age 10–14 y | Age 15–19 y |
 | --- | --- | --- | --- |
 | Taking care of woundb | N = 1287 | n = 830 | n = 457 |
 | Not at all confident | 28 (2.2) | 18 (2.2) | 10 (2.2) |
 | Not very confident | 49 (3.8) | 43 (5.2) | 6 (1.3) |
 | Somewhat confident | 127 (9.9) | 97 (11.7) | 30 (6.6) |
 | Very confident | 1083 (84.2) | 672 (81.0) | 411 (89.9) |
 | Refraining from masturbating/doing self-sexc | N = 1283 | n = 826 | n = 457 |
 | Not at all confident | 15 (1.2) | 11 (1.3) | 4 (0.9) |
 | Not very confident | 19 (1.5) | 16 (1.9) | 3 (0.7) |
 | Somewhat confident | 38 (3.0) | 23 (2.8) | 15 (3.3) |
 | Very confident | 478 (37.3) | 184 (22.3) | 294 (64.3) |
 | Does not masturbate | 733 (57.1) | 592 (71.7) | 141 (30.9) |
 | Refraining from sex for 6 wk after circumcisiond | N = 1288 | n = 832 | n = 456 |
 | Not at all confident | 7 (0.5) | 5 (0.6) | 2 (0.4) |
 | Not very confident | 16 (1.2) | 8 (1.0) | 8 (1.8) |
 | Somewhat confident | 58 (4.5) | 26 (3.1) | 32 (7.0) |
 | Very confident | 481 (37.3) | 157 (18.9) | 324 (71.1) |
 | Not sexually active | 726 (56.4) | 636 (76.4) | 90 (19.7) |
 | Refraining from sex for 6 wk even if partner wants to have sexe | N = 561 | n =

[Assistant]
195 | n = 366 |
 | Not at all confident | 16 (2.8) | 10 (5.1) | 6 (1.6) |
 | Not very confident | 19 (3.4) | 7 (3.6) | 12 (3.3) |
 | Somewhat confident | 56 (10.0) | 27 (13.9) | 29 (7.9) |
 | Very confident | 470 (83.8) | 151 (77.4) | 319 (87.2) | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> | <ROWSPAN=2-COLSPAN=2> Associated anomalies | Right isomerism | Left isomerism |
 | Biventricular AV connection (l-loop) 2 hearts | Absent left AV connection (l-loop) 1 heart |
 | --- | --- | --- | --- |
 | <COLSPAN=2> Dextrocardia | 2 | 1 |
 | <COLSPAN=2> Persistent left SVC to left sided atrium | 2 | 1 |
 | <COLSPAN=2> Interrupted IVC | – | 1 |
 | <COLSPAN=2> Totally anomalous pulmonary venous drainage into right SVC | 2 | – |
 | <COLSPAN=2> Absent coronary sinus | 2 | – |
 | <COLSPAN=2> ASD/PFO | 1/– | –/1 |
 | <COLSPAN=2> Common atrium | 1 | – |
 | <COLSPAN=2> AV septal defect | 2 | – |
 | <COLSPAN=2> Muscular VSD | – | 1 |
 | <COLSPAN=2> Subaortic infundibulum | 2 | 1 |
 | Left outlet obstruction | Fibrous diaphragm | 1 | – |
 | <COLSPAN=2> Bicuspid pulmonary valve | 2 | 1 |
 | <COLSPAN=2> Right aortic arch | 2 | 1 |
 | <COLSPAN=2> PDA (left/right) | 1/– | –/– | </md>


[User] <|image|>Express the figure as Markdown code.

[Assistant]
<md> | <ROWSPAN=2> Cause categories | <COLSPAN=4> Males | <COLSPAN=4> Females |
 | SEYLL | SEYLLpper 1,000 | % | Rank | SEYLL | SEYLLpper 1,000 | % | Rank |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Cardiovascular diseases | 451330.7 | 24.2 | 31.9 | 1 | 296627.1 | 14.9 | 35.6 | 1 |
 | Malignant tumors | 358135.6 | 19.2 | 25.3 | 2 | 291951.4 | 14.7 | 35.0 | 2 |
 | Unintentional injuries | 202599.0 | 10.9 | 14.3 | 3 | 44526.4 | 2.2 | 5.3 | 4 |
 | Intentional injuries | 98557.6 | 5.3 | 7.0 | 4 | 14052.7 | 0.7 | 1.7 | 9 |
 | Digestive diseases | 94725.0 | 5.1 | 6.7 | 5 | 44872.8 | 2.3 | 5.4 | 3 |
 | Mental and neurological conditions | 42068.0 | 2.3 | 3.0 | 6 | 21446.0 | 1.1 | 2.6 | 6 |
 | Perinatal and infant causes | 34096.2 | 1.8 | 2.4 | 7 | 26863.3 | 1.4 | 3.2 | 5 |
 | Respiratory diseases | 33612.4 | 1.8 | 2.4 | 8 | 16966.5 | 0.9 | 2.0 | 8 |
 | Respiratory infections | 32912.0 | 1.8 | 2.3 | 9 | 21006.7 | 1.1 | 2.5 | 7 |
 | Infectious and parasitic diseases | 19562.2 | 1.0 | 1.4 | 10 | 11032.4 | 0.6 | 1.3 | 10 | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> | Last Vaccine Dose (Manufacturer) | No. of Horses (%) | Vaccine Breakdown (%) | No. of Days Since V2 | No. of Days Since V3 or Subsequent Booster | Representative H3N8 American Lineage Vaccine Strain |
 | --- | --- | --- | --- | --- | --- |
 | Duvaxyn IET Plus (Elanco Animal Health) | 43 (44%) | 13/43 (30%) | 124 (n = 1) | 276 ± 27.7 SE (n = 12) | A/eq/Newmarket/1/93 |
 | Equip FT (Zoetis) | 10 (10%) | 5/10 (50%) | 189 (n = 1) | 267 ± 51.2 SE (n = 4) | A/eq/Kentucky/98 |
 | Equilis Prequenza Te (MSD Animal Health) | 32 (33%) | 9/32 (28%) | 135 ± 33.5 SE (n = 2) | 217 ± 35.7 SE (n = 7) | A/eq/South Africa/4/03 1 |
 | ProteqFlu Te (Merial) | 13 (13%) | 3/13 (23%) | 42 (n = 1) | 257 ± 95.5 SE (n = 2) | A/eq/Ohio/03 2 |
 | Total/average | 98 | 30/98 (31%) | 125 ± 25.9 SE (n = 5) | 261 ± 19.6 SE (n = 25) |  | </md>


[User]
<|image|>Continue parse the photo with markdown style: <md> |  | Mean intra-participant difference in FeNO (ppb) (95% CI) [p-value] * | Standard deviation (SD) of the intra-participant difference in FeNO (ppb) | 95% limits of agreement (ppb) |
 | --- | --- | --- |

[Assistant]
--- |
 | All participants | 1.37 | 4.58 | -7.61 to 10.34 |
 | (n = 494) | (0.96, 1.77) [<0.001] |  |  |
 | Males | 1.43 | 4.97 | -8.30 to 11.17 |
 | (n = 251) | (0.82, 2.05) [<0.001] |  |  |
 | Females | 1.30 | 4.15 | -6.83 to 9.43 |
 | (n = 243) | (0.77, 1.82) [<0.001] |  |  |
 | Participants with a low FEV1 | 2.01 | 5.21 | -8.20 to 12.22 |
 | (n = 162) | (1.20, 2.81) [<0.001] |  |  |
 | Participants with a high FEV1 | 1.07 | 3.75 | -6.28 to 8.42 |
 | (n = 162) | (0.49, 1.65) [<0.001] |  |  |
 | Participants with asthma | 2.37 | 7.01 | -11.38 to 16.12 |
 | (n = 71) | (0.71, 4.03) [0.006] |  |  |
 | All others participants | 1.19 | 4.09 | -6.82 to 9.20 |
 | (n = 401) | (0.79, 1.59) [<0.001] |  |  | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> |  | Baseline | Melatonin Supplementation |
 | --- | --- | --- |
 | AI | 6.2 (3.8–22.5) | 5.8 (3.3–33.5) |
 | AHI | 7.6 (3.6–57.7) | 3.5 (1.2–48.6) |
 | Stage 1% | 1.3 (0–4.4) | 2.2 (1.7–2.9) |
 | Stage 2% | 45.9 (32.7–68.7) | 61.3 (40–68.5) |
 | Stage 3% | 15.8 (4.1–35.1) | 19 (3.4–32.3) |
 | Stage 4% | 14.6 (0–30) | 10.9 (0–13.4) |
 | Stage REM% | 13.1 (7.8–36.1) | 14.2 (10.8–25.2) |
 | REM latency | 92 (63.5–169.5) | 152.5 (66.5–213.5) |
 | TST | 332.5 (90–353.5) | 338.5 (292–365) |
 | SpO2 < 90% | 0.6 (0–37.6) | 0.8 (0.4–21.1)

[Assistant]
|
 | # Awake times | 7 (4–24) | 7 (4–40) |
 | Time spent awake | 16 (6–149) | 20 (5–136.5) | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> | Module | Technical characteristics |
 | --- | --- |
 | Oxygenator |  |
 | Type | CAPIOX® RX15E |
 | Priming volume (static) | 135 mL |
 | Membrane surface area | approx. 1,5 m2 |
 | Fiber material | microporous polypropylene |
 | Bubble trap |  |
 | Type | CAPIOX®BT15X |
 | Priming volume | 150 mL |
 | Filter pore area | 60% |
 | Filter pore size | 170 μ |
 | Filter material | Polyester |
 | Arterial filter |  |
 | Type | Terumo® AL8X |
 | Priming volume | 170 mL |
 | Filter area | 0,063 m2 |
 | Filter pore size | 40 μ |
 | Filter material | Polyester |
 | Centrifugal pump head |  |
 | Type | SarnsTM 164275X |
 | Priming volume | 48 mL |
 | Surface area | 0,02 m2 |
 | Total component priming volume | 503 mL | </md>


[User] <|image|>Convert the illustration to Markdown syntax.

[Assistant]
<md> | Patient | VEF component | Deficit of BIT-C | Neglect component | Brain lesion |
 | --- | --- | --- | --- | --- |
 | Patient 1 | N145 | Bisection cancelation | Perceptual/visuo-spatial | PPC, PFL |
 |  |  |  | Exploratory/oculo-motor |  |
 | Patient 2 | P100 | Copying, drawing cancelation | Allocentric/object-based | TPJ, TL, PFL |
 |  |  |  | Exploratory/oculo-motor |  |
 | Patient 3 | not related | Cancelation only | Exploratory/oculo-motor | TL, IFL | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | Characters | Mean ± standard error | Standard deviation | Range |
 | --- | --- | --- | --- |
 | % Root emergence (RE %) | 48.00 ± 7.86 | 24.85 | 10–90 |
 | Number of emerged buds/nursery plant (NB) | 0.54 ± 0.13 | 0.89 | 0–3 |
 | Length of nursery plant (LP cm) | 28.08 ± 2.23 | 15.47

[Assistant]
| 4–70 |
 | Diameter of nursery plant (DP mm) | 11.96 ± 0.92 | 6.43 | 5–45 |
 | Number of leaves/nursery plant (NL) | 18.96 ± 1.77 | 12.29 | 3–63 |
 | Cumulative growth of nursery plant (CG cm) | 60.44 ± 2.60 | 18.03 | 32–112 |
 | Number of roots/nursery plant (NR) | 15.02 ± 1.29 | 8.93 | 1–39 | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | Material | Proportion of plastron covering the surface as imaged by confocal microscope | Plastron coverage numerical value | Plastron coverage/(Density × Thickness) | %O2 for box in water after 6 h |
 | --- | --- | --- | --- | --- |
 | Speedo LZR Pulse® | Covering surface | 5 | 45 ± 10 | 12.4 ± 0.1 |
 | PTFE Tape | None visible | 5 | 42 ± 3 | 12.3 |
 | Gore-Tex | Covering surface | 5 | 23 ± 5 | 11.6 |
 | Furtech Polyester | Plastron between fabric weave | 3 | 40 ± 14 | 11.6 |
 | D P Polyester | Covering surface | 5 | 25 ± 12 | 11.6 |
 | D P Polyester Reverse | Partial surface coverage | 4 | 20 ± 10 | 11.4 |
 | Toray Nylon | None visible | 1 | 20 ± 5 | 10.6 |
 | Toray Polyester | Bubbles on surface | 2 | 19 ± 6 | 9.3 |
 | Speedo Fastskin® | Covering surface | 5 |

[Assistant]
21 ± 3 | 5.7 |
 | Speedo Aquablade® | None visible | 1 | 4 ± 1 | 5.0 |
 | Speedo Endurance® | Partial surface coverage | 4 | 19 ± 3 | 4.3 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Characteristics | ICASO | Controls |
 | --- | --- | --- |
 | Number of the participants | 715 | 507 |
 | <COLSPAN=3> Age (yrs) |
 | Mean ± SD | 58.4 ± 12.9 | 37.2 ± 16.9 |
 | Range | 15–89 | - |
 | Female, n (%) | 253 (35.4) | 377 (74.4) |
 | <COLSPAN=3> Conventional risk factors, n (%) |
 | Hypertension | 429 (60.0) | - |
 | Diabetes | 179 (25.0) | - |
 | Hyperlipemia | 290

[Assistant]
(40.6) | - |
 | Coronary heart diseases | 79 (11.0) | - |
 | Smoking | 277 (38.7) | - |
 | Drinking | 150 (21.0) | - |
 | <COLSPAN=3> RNF213 p.R4810K genotype |
 | Wild type: GG (%) | 709 (99.16) | 505 (99.61) |
 | Heterozygous: GA (%) | 6 (0.84) | 2 (0.39) |
 | Homozygous: AA (%) | 0 (0) | 0 (0) |
 | OR (95% confidence interval) | 2.14 (0.43–10.63) |  |
 | p value | 0.56 |  | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | Scale | PSBS t1_3b | PSBS t7_3b | n | z | p |
 | --- | --- | --- | --- | --- | --- |
 | 1. Psychosomatic symptom complex | 6.81 (3.16) | 6.94 (3.00) | 513 | -6.35 | < .01 |
 | 2. Gastrointestinal symptom complex | 0.82 (1.30) | 0.51 (0.96) | 514 | -5.47 | < .01 |
 | 3. Respiratory symptom complex | 1.84 (1.58) | 1.79 (1.45) | 513 | -2.41 | < .01 |
 | 4. Sweatinga | 0.35 (0.76) | 0.24 (0.60) | 506 | -0.34 | .73 |
 | 5. Paina | 1.99 (0.95) | 1.70 (0.80) | 512 | -2.85 | < .01 |
 | 6. Itchinga | 0.21 (0.55) | 0.27 (0.61) | 513 | -3.14 | < .01 |
 | Sum score | 12.21 (4.40) | 11.70 (4.13) | 514 | -2.02 | < .01 | </md>


[User] <|image|>Render the photo in Markdown format.

[Assistant]
<md> | Mutation Type | Number | Frequency (%) |
 | --- | --- | --- |
 | A→T/T→A | 1 | 1.05 |
 | A→C/T→G | 2 | 2.1 |
 | A→G/T→C | 0 | 0 |
 | G→A/C→T | 24 | 25.3 |
 | G→C/C→G | 4 | 4.2 |
 | G→T/C→A | 2 | 2.1 |
 | Insertions | 20 |  |
 | Deletions | 42 | 44.2 |
 | Total | 95 | 100 |
 | A→N/T→N | 3 | 3.16 |
 | G→N/C→N | 30 | 31.6 |
 | Transitions | 24 | 25.3 |
 | Transversions | 9 | 9.5 | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> | <COLSPAN=7> Cerebellar subjects | <COLSPAN=3> Controls |
 | ID | Age | Sex | Diagnosis | Disease duration | ICARS (total/100) | ICARS UL (total/20) | ID | Age | Sex |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | P01 | 30 | M | SAOA | 9 years | 38.5 | 7.5 | C01 | 28 | M |
 | P02 | 47 | M | ADCA III | 12 years | 43.5 | 4.5 | C02 | 33 | M |
 | P03 | 47 | M | ADCA III | 17 years | 32.5 | 4.5 | C03 | 47 | M |
 | P04 | 48 | F | ADCA III | 28 years | 19 | 1 | C04 | 47 | M |
 | P05 | 48 | M | SCA 14 | 25 years | 20 | 3 | C05 | 50 | F |
 | P06 | 50 | F | SCA 14 | 17 years | 17 | 1 | C06 | 51 | F |
 | P07 | 52 | M | ADCA III | 6 years | 19.5 | 3 | C07 | 52 | M |
 | P08 | 53 | M | Cerebellitis | 10 years | 46 | 5 | C08 | 54 | M |
 | P09 | 54 | F | SCA 14 | 25 years | 27 | 3.5 | C09 | 55 | M |
 | P10 | 54 | F | SAOA | 18 years | 31 | 4.5 | C10 | 55 | M |
 | P11 | 55 | M | SAOA | 18 years | 48 | 5 | C11 | 55 | F |
 | P12 | 58 | F | SCA 6 | 8 years | 43.5 | 10 | C12 | 57 | F |
 | P13 | 60 | F | ADCA III | 13 years | 23 | 11 | C13 | 63 | F |
 | P14 | 61 | M | SCA 6 | 4 years | 9 | 0 | C14 | 65 | M | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Number of | <COLSPAN=6> CNN statistical measures (%) |
 | features | Accuracy | Sensitivity | Specificity | Precision | F-score | MCC |
 | --- | --- | --- | --- | --- | --- | --- |
 | 250 | 53.66 | 53.18 | 96.14 | 52.87 | 53.03 | 49.81 |
 | 1258 | 67.55 | 68.58 | 97.44 | 68.30 | 68.44 | 64.85 |
 | 1298 | 69.22 | 68.61 | 97.43 | 68.59 | 68.60 | 66.65 |
 | 6443 | 74.69 | 74.13 | 97.89 | 74.09 | 74.11 | 72.59 |
 | 6483 | 74.60 | 74.01 | 97.88 | 73.97 | 73.99 | 72.48 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> |  |  |  | <COLSPAN=3> Independent association with ready availability of an approved sharps disposal containera |
 | Behaviour

[Assistant]
| Number of appointments (%) | Number of clinics (%) | OR | 95 % CI | p |
 | --- | --- | --- | --- | --- | --- |
 | Uncapping of needle using the mouth | 350/1353 (26) | 41/47 (87) | ND | ND | ND |
 | Recapping of needle | 1137/1353 (84) | 47/47 (100) | 0.46 | 0.15–1.38 | 0.167 |
 | Bare sharp left out | 237/1359 (17) | 38/47 (81) | 0.78 | 0.43–1.43 | 0.431 |
 | All visible sharps placed in disposal container prior to end of appointment | 513/1359 (38) | 39/47 (83) | 15.00 | 6.67–33.73 | <0.001 | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <ROWSPAN=2> Seroconversion,a Time Point | <COLSPAN=2> MV, YFV, MenAV, and PRV | <COLSPAN=2> MV, YFV, and MenAV | <ROWSPAN=2> Difference, Percentage Points (95% CI) |
 | Proportion |

[Assistant]
Percentage (95% CI) | Proportion | Percentage (95% CI) |
 | --- | --- | --- | --- | --- | --- |
 | Day 28 | 255/261 | 97.7 (95.9–99.5) | 246/252 | 97.6 (95.7–99.5) | 0.1 (−4.0–4.2) |
 | Day 84 | 210/228 | 92.1 (88.6–95.6) | 206/218 | 94.5 (91.5–97.5) | −2.4 (−7.5–2.7) | </md>


[User] <|image|>Transform the photo into Markdown format.

[Assistant]
<md> | Diameter of the largest fibroid nodule | Frequency | Percentage |
 | --- | --- | --- |
 | <3 cm | 30 | 33.3 |
 | 3–4.9 cm | 28 | 31.1 |
 | 5 cm and above | 32 | 35.6 |
 | Total | 90 | 100.0 | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | Gene symbol | Gene name |
 | --- | --- |
 | <COLSPAN=2> Increased in SFM vs. PBM |
 | HSPA1A | Heat shock 70 kDa protein 1A |
 | BCL2L1 | BCL2-like 1 (BCL-XL/S) |
 | BAG3 | BCL2-associated athanogene 3 |
 | MAPK7 | Mitogen-activated protein kinase 7 (ERK5) |
 | HSPA6 | Heat shock 70 kDa protein 6 (HSP70B) |
 | MAPK8 | Mitogen-activated protein kinase 8 (JNK1) |
 | HSPA2 | Heat shock 70 kDa protein 2 |
 | BCL2 | B-cell CLL/lymphoma 2 |
 | TNFRSF10D | TNF Receptor Superfamily, Member 10d, decoy with Truncated Death Domain (TRAIL4) |
 | XIAP | X-linked inhibitor of apoptosis |
 | MAP4K3 | Mitogen activated protein kinase kinase kinase kinase 3 |
 | CASP7 | Caspase-7, apoptosis-related cysteine peptidase |
 | TMBIM6 | Transmembrane BAX inhibitor motif containing 6 |
 | ATF2 | Activating transcription factor 2 (CREB2) |
 | HSPA5 | Heat shock 70 kDa protein 5 (glucose regulated protein 78 kDa) |
 | PIK3CB | Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
 | <COLSPAN=2> Decreased in SFM vs. PBM |
 | HSPA1L | Heat shock 70 kDa protein 1-like |
 | LTB | Lymphotoxin beta (TNF superfamily, member 3) (TNFSF3) |
 | PRKCB | Protein kinase C, beta |
 | MAP4K2 | mitogen-activated protein kinase kinase kinase kinase 2 |
 | FOS | FBJ murine osteosarcoma viral oncogene homolog |
 | CASP10 | caspase 10, apoptosis-related cysteine peptidase (ALPS2, FLICE2) |
 | CASP8 | caspase 8, apoptosis-related cysteine peptidase (ALPS2B, FLICE) |
 | BCL2L11 | BCL2-Like 11 (Apoptosis Facilitator) (BIM) |
 | APAF1 | Apoptotic Peptidase Activating Factor 1 |
 | MAP3K5 | Mitogen-activated protein kinase kinase kinase 5 |
 | BAG4 | BCL2-associated athanogene 4 |
 | PIK3CD | Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
 | TP53 | Tumor protein p53 |
 | TNFRSF10C | Tumor Necrosis Factor Receptor Superfamily, Member 10c, decoy without an intracellular domain | </md>


[User] <|image|>Interpret the photo as Markdown format.

[Assistant]
<md> | Variable | Total | Sirt1-positive | Sirt1-negative | P-value |
 | --- | --- | --- | --- | --- |
 | No. of patients, n (%) | 125 (100) | 26 (20.8) | 99 (79.2) | NA |
 | Age, years | 85±8.685 | 70.46±4.623 | 66.83±9.307 | 0.617 |
 | Mean ± SD (range) | (42–84) | (60–79) | (42–84) | NA |
 | Gender, n (M/F) | 71/54 | 19/7 | 52/47 | 0.600 |
 | Succumbed/remained, n | 30/95 | 8/18 | 22/77 | 0.364 |
 | <COLSPAN=5> T factor, n |
 | TI/T2/T3/T4 | 68/43/4/10 | 12/9/1/4 | 56/34/3/6 | 0.442 |
 | <COLSPAN=5> N factor, n |
 | N0/N1/N2/N3 | 87/13/24/1 | 14/7/5/0 | 73/6/19/1 | 0.018a |
 | <COLSPAN=5> M factor, n |
 | M0/M1 | 122/3 | 24/2 | 98/1 | 0.048a |
 | <COLSPAN=5> TNM stage, n |
 | I/II/III/IV | 82/12/31/0 | 12/7/7/0 | 70/5/24/0 | 0.002a |
 | <COLSPAN=5> PA invasion, n |
 | Positive/negative | 24/101 | 7/19 | 17/82 | 0.261 |
 | <COLSPAN=5> PV invasion, n |
 | Positive/negative | 51/74 | 17/9 | 34/65 | 0.004a |
 | <COLSPAN=5> LY invasion, n |
 | Positive/negative | 50/75 | 15/11 | 35/64 | 0.039a |
 | <COLSPAN=5> p53 expression, n |
 | Positive/negative | 67/58 | 14/12 | 53/46 | 0.977 |
 | <COLSPAN=5> HIFI expression, n |
 | Positive/negative | 39/86 | 4/22 | 35/64 | 0.050a |
 | <COLSPAN=5> Ki67 index, n |
 | Positive/negative | 111/14 | 26/0 | 85/14 | 0.002 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | Immune cells | Other cells |
 | --- | --- |
 | Mast cells | Endothelial cells |
 | Lymphocytes | Vascular smooth muscle cells |
 | Macrophages | Fibroblasts/myofibroblasts |
 | Dendritic cells | Platelets |
 | Neutrophils

[Assistant]
| Adipocytes |
 |  | Perivascular nerves | </md>


[User] <|image|>Render the image in Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Location of lobe | <ROWSPAN=2> Area (m2) | <ROWSPAN=2> Length (m) | <ROWSPAN=2> Max. width (m) | <ROWSPAN=2> Elevation at front (m a.s.l.) | <ROWSPAN=2> Mean slope (°) | <ROWSPAN=2> Aspect (class) | <ROWSPAN=2> Frontal height of lobe (riser) (cm) | <COLSPAN=2> Vegetation cover | <ROWSPAN=2> Landform* | <ROWSPAN=2> Geology** |
 | riser | tread |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Fallbichl | 6474 | 251 | 67 | 2247 | 29.5 | NW | 90 | closed | closed | TBL | CMS |
 | Elisabethfelsen | 71 | 18 | 9 | 2105 | 22.2 | NNW | 50 | sparse | sparse | SBL | MR |
 | Seeschartl | 70 | 18 | 12 | 2593 | 18.5 | SE | 45 | sparse | no | SBL | OG |
 | Hinteres Langtal cirque - south-west facing slope | 616 | 74 | 22 | 2391 | 34.6 | SW | 60 | sparse | sparse | TBL | MS |
 | Hinteres Langtal cirque - north-east facing slope | 1661 | 105 | 44 | 2406 | 35.3 | NNE | 55 | sparse | sparse | TBL | MS | </md>


[User] <|image|>Continue parse the table with markdown style: <md> |  | Pre-op(Mean ± SD) | Post-op(Mean ± SD) | P value |

[Assistant]
| --- | --- | --- | --- |
 | Spherical equivalent (D) | −3.60 ± 1.54 | − 0.08 ± 0.36 | < 0.0001* |
 | Cylinder (D) | 0.79 ± 0.74 | 0.16 ± 0.21 | < 0.001* |
 | Predictability within ±0.50 D (%) | – | 85% for Seq97% for Ast | – |
 | Predictability within ±1.00 D (%) | – | 97% for Seq100% for Ast | – | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Biomarker | <COLSPAN=2> Overall | <COLSPAN=2> P&D drivers | <COLSPAN=2> Dockworkers | <COLSPAN=2> Office clerks |
 |  | Mean (±SD) | GM (±GSD) | Mean (±SD) | GM (±GSD) | Mean (±SD) | GM (±GSD) | Mean (±SD) | GM (±GSD) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | ICAM-1 (ng/mL) | 202 ± 40 | 198 ± 1.22 | 208 ± 42 | 203 ± 1.23 | 216 ± 34 | 213 ± 1.17 | 181 ± 32 | 178 ± 1.19 |
 | VCAM-1 (ng/mL) | 677 ± 131 | 661 ± 1.21 | 679 ± 144 | 663 ± 1.23 | 673 ± 123 | 658 ± 1.21 | 675 ± 115 | 661 ± 1.19 |
 | IL-6 (pg/mL) | 1.38 ± 1.20 | 1.09 ± 1.71 | 1.36 ± 0.79 | 1.12 ± 1.59 | 1.50 ± 2.17 | 0.98 ± 2.14

[Assistant]
| 1.30 ± 0.82 | 1.11 ± 1.61 |
 | CRP (mg/L) | 1.66 ± 1.80 | 1.00 ± 2.63 | 1.53 ± 1.51 | 1.01 ± 2.36 | 1.72 ± 1.68 | 0.98 ± 3.18 | 1.87 ± 2.41 | 1.01 ± 2.90 |
 | 8-OHdG (μg/g creat.) | 55.9 ± 31.5 | 47.7 ± 1.79 | 58.9 ± 32.9 | 49.3 ± 1.90 | 52.8 ± 36.1 | 45.8 ± 1.67 | 52.3 ± 25.4 | 46.0 ± 1.72 | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | mRNA | Primers |
 | --- | --- |
 | MOR-1 | F: 5′-ATGCCAGTGCTCATCATTAC-3′R: 5′-GATCCTTCGAAGATTCCTGTCCT-3′ |
 | β-actin

[Assistant] | F: 5′-GATGAGATTGGCATGGCTTT-3′R: 5′-CACCTTCACCGTTCCAGTTT-3′ | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Substitution type | <COLSPAN=3> Fixed substitutions | <COLSPAN=3> SNPs |
 |  | Low GC | High GC | p | Low GC | High GC | p |
 | --- | --- | --- | --- | --- | --- | --- |
 | A/T -> C/G | 0.00049 | 0.00057 | 4.1 × 10-1 | 0.00020 | 0.00014 | 7.6 × 10-1 |
 | A/T -> G/C | 0.00214 | 0.00257 | 6.9 × 10-2 | 0.00069 | 0.00074 | 7.3 × 10-1 |
 | A/T -> T/A | 0.00049 | 0.00043 | 5.0 × 10-1 | 0.00018 | 0.00014 | 6.6 × 10-1 |
 | C/G -> G/C |

[Assistant]
0.00088 | 0.00080 | 5.5 × 10-1 | 0.00031 | 0.00028 | 9.0 × 10-1 |
 | C/G -> A/T | 0.00095 | 0.00075 | 1.3 × 10-1 | 0.00035 | 0.00027 | 2.9 × 10-1 |
 | C/G -> T/A | 0.00275 | 0.00268 | 7.3 × 10-1 | 0.00105 | 0.00109 | 1 |
 | CpG -> TpG | 0.03226 | 0.02081 | 7.3 × 10-3 | 0.01464 | 0.01300 | 6.7 × 10-1 |
 | GC* | 0.35548 | 0.41816 | 1.3 × 10-4 | 0.35703 | 0.38604 | 3.7 × 10-1 |
 | Number of sites (Mb) | 0.96 | 0.44 | - | 0.96 | 0.44 | - | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | Organisms | Antibiotics | Concentration (μg/mL) | Fold enhancement of activity |
 | --- | --- | --- | --- |
 | <ROWSPAN=6> E. coli (CA8000) | Rifampicin | 20.0 | 38.8 |
 | Rifampicin | 30.0 | 12.6 |
 | Ampicillin | 6.0 | 5.3 |
 | Tetracycline | 1.0 | 2.3 |
 | Tetracycline | 2.0 | 5.2 |
 | Nalidixic acid | 6.0 | 50.0 |
 | <ROWSPAN=4> B. subtilis (MTCC121) | Rifampicin | 0.05 | 19.4 |
 | Ampicillin | 0.01 | 5.1 |
 | Tetracycline |

[Assistant]
1.0 | 3.5 |
 | Nalidixic acid | 2.0 | 7.0 |
 | <ROWSPAN=4> M. smegmatis (MC2 155) | Rifampicin | 0.05 | 1.9 |
 | Ampicillin | 0.01 | 4.7 |
 | Tetracycline | 1.0 | 4.0 |
 | Nalidixic acid | 2.0 | 1.2 | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> |  | Peds1 | Peds2 | Peds3 | Peds4 | Adults [14] |
 | --- | --- | --- | --- | --- | --- |
 | n | 144 | 118 | 108 | 214 |

[Assistant]
506 |
 | Sensitivity (%) | 75 | 58 | 91 | 93 | 92 |
 | Specificity (%) | 73 | 90 | 71 | 36 | 62 |
 | Positive predictive value (%) | 40 | 39 | 26 | 18 | 16 |
 | Negative predictive value (%) | 92 | 95 | 99 | 97 | 99 |
 | ROC AUCa | 0.77 | 0.74 | 0.81 | 0.80 | n/a | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | <COLSPAN=4>  | <COLSPAN=3> Exclusion power Pu |
 | Type of markers | Size of factorial design (Nf x Nm) | Alleles/ locusa | Number of loci | Predicted (Eq.2)* | Simulated | Predicted (Eq.7)** |
 | --- | --- | --- | --- | --- | --- | --- |
 | Idealized markers (equally frequent alleles) | 10x10 | 5 | 3 | 0.3064 | 0.2123 | 0.1104 |
 |  | 10x10 | 5 | 6 | 0.9861 | 0.9163 | 0.9131 |
 |  | 10x10 | 5 | 9 | 0.9998 | 0.9947 | 0.9946 |
 |  | 10x10 | 5 | 12 | 1.0000 | 0.9997 | 0.9996 |
 |  | 10x10 | 10 | 3 | 0.9690 | 0.8448 | 0.8334 |
 |  | 10x10 | 10 | 6 | 1.0000 | 0.9987 | 0.9986 |
 |  | 20x20 | 5 | 3 | 0.0085 | 0.0321 | 0.0001 |
 |  | 20x20 | 5 | 6 | 0.9453 | 0.8143 | 0.8037 |
 |  | 20x20 | 5 | 9 | 0.9993 | 0.9884 | 0.9884 |
 |  | 20x20 | 5 | 12 | 1.0000 | 0.9993 | 0.9993 |
 |  | 20x20 | 10 | 3 | 0.8810 | 0.6717 | 0.6409 |
 |  | 20x20 | 10 | 6 | 1.0000 | 0.9972 | 0.9971 |
 | Real microsatellites | 76x13 | 20.1 | 8 | 1.0000 | 0.9994 | 0.9993 |
 |  | 75x26 | 21.7 | 6 | 0.9999 | 0.9934 | 0.9934 |
 |  | 41x8 | 19.3 | 6 | 0.9999 | 0.9928 | 0.9920 |
 |  | 20x2 | 16.3 | 4 | 0.9986 | 0.9465 | 0.9421 |
 |  | 147x8 | 7.5 | 8 | 0.9911 | 0.8604 | 0.8636 |
 |  | 96x8 | 7.6 | 8 | 0.9975 | 0.9473 | 0.9422 |
 |  | 24x10 | 7.8 | 8 | 0.9990 | 0.9712 | 0.9782 |
 |  | 100x101 | 7.5 | 12 | 0.9968 | 0.9708 | 0.9696 | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | <COLSPAN=2>  | % | Patient number (n) |
 | --- | --- | --- | --- |
 | <COLSPAN=2> Additional findings with congenital SV pathologies | 57,1 | 24 |
 |  | Ipsilateral VD agenesis | 11,9 | 5 |
 |  | Ipsilateral renal agenesis | 9,5 | 4 |
 |  | Bilateral VD agenesis | 4,8 | 2 |
 |  | Bilateral VD hypoplasia | 2,4 | 1 |
 |  | Ipsilateral VD hypoplasia | 2,4 | 1 |

[Assistant]
 |  | Ipsilateral ectopic kidney | 2,4 | 1 |
 |  | Contralateral pelvic kidney | 2,4 | 1 |
 |  | Ipsilateral undescended testis | 2,4 | 1 |
 |  | Utricle cyst | 2,4 | 1 |
 | <COLSPAN=2> Additional findings with acquired SV pathologies | 42,9 | 18 |
 |  | BPH | 50 | 9 |
 |  | Contralateral ectopic kidney | 5,5 | 1 |
 |  | SV dilatation | 5,5 | 1 | </md>


[User] <|image|>Continue parse the table with markdown style: <md> | <ROWSPAN=2> Treatment of right flank organ with testosterone or DHT + ethanol or SPS | <COLSPAN=2> Flank organ growth (mm2) | <ROWSPAN=2> Difference between left and right flank organ growth (mm2) |

[Assistant]
 | Left (untreated) | Right (treated) |
 | --- | --- | --- | --- |
 | Testosterone + ethanol (control) | 1.4 ± 2.7 | 8.5 ± 1.8 | 7.1 ± 2.3 |
 | Testosterone + HLLP SPS | 3.2 ± 1.5 | 2.1 ± 1.2 | −1.2 ± 1.9 |
 | Testosterone + HLHP SPS | 2.2 ± 1.7 | 2.8 ± 2.6 | 0.6 ± 1.5 |
 | Testosterone + HMLP SPS | 1.8 ± 1.5 | 3.2 ± 1.8 | 1.4 ± 2.7 |
 | DHT + ethanol (control) | 0.2 ± 1.7 | 4.8 ± 3.2 | 4.6 ± 4.1 |
 | DHT + HLLP SPS | 5.2 ± 2.2 | 7.4 ± 1.8 | 2.1 ± 1.3 |
 | DHT + HLHP SPS | 0.7 ± 2.0 | 4.1 ± 2.0 | 3.4 ± 2.9 |
 | DHT + HMLP SPS | 4.6 ± 1.9 | 8.3 ± 3.4 | 3.7 ± 2.4 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Planta | Metal contaminants | Location | Comment and reference |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Anacardiaceae |
 | Pistacia terebinthus Bieberstein | Cu | Cyprus | Field study using chicken fertilizer and 1:1 soil and mine waste (Johansson et al. 2005) |
 | Schinus molle L. | Cd, Cu, Mn, Pb, Zn | Mexico | Plant survey (Gonzalez and Gonzalez-Chavez 2006) |
 | <COLSPAN=4> Asteraceae |
 | Baccharis neglecta Britt. | As | Mexico | Plant survey (Flores-Tavizon et al. 2003) |
 | Bidens humilis H.B.K. | Ag, As, Cd, Cu, Pb, Zn

[Assistant]
| Ecuador | Plant survey (Bech et al. 2002) |
 | Isocoma veneta (Kunth) Greene | Cd, Cu, Mn, Pb, Zn | Mexico | Plant survey (Gonzalez and Gonzalez-Chavez 2006) |
 | Viguiera linearis (Cav.) Sch. |
 | <COLSPAN=4> Chenopodiaceae |
 | Teloxys graveolens (Willd.) W.A. Weber | Cd, Cu, Mn, Pb, Zn | Mexico | Plant survey (Gonzalez and Gonzalez-Chavez 2006) |
 | Atriplex lentiformis (Torr.) S. Wats. | As, Cu, Mn, Pb, Zn | U.S. | Greenhouse study using compost (Mendez et al. 2007) |
 | Atriplex canescens (Pursh) Nutt. | As, Hg, Mn, Pb | U.S. | Field study (Rosario et al. 2007) |
 | <COLSPAN=4> Euphorbiaceae |
 | Euphorbia sp. | Cd, Cu, Mn, Pb, Zn | Mexico | Plant survey (Gonzalez and Gonzalez-Chavez 2006) |
 | <COLSPAN=4> Fabaceae |
 | Dalea bicolor Humb. & Bonpl. ex Willd. | Cd, Cu, Mn, Pb, Zn | Mexico | Plant survey (Gonzalez and Gonzalez-Chavez 2006) |
 | <COLSPAN=4> Plumbaginaceae |
 | Lygeum spartum L. | Cu, Pb, Zn | Spain | Plant survey (Conesa et al. 2006) |
 | <COLSPAN=4> Poaceae |
 | Piptatherum miliaceum (L.) Coss. | Cu, Pb, Zn | Spain | Plant survey (Conesa et al. 2006) | </md>


[User] <|image|>Convert the table to Markdown syntax.

[Assistant]
<md> |  | <COLSPAN=2> Frequency of events reported | <COLSPAN=2> Overall perception of safety |
 |  | Pearson r | N | Pearson r | N |
 | --- | --- | --- | --- | --- |
 | Supervisor/Manager expectations and actions promoting safety | 0.081* | 1328 | 0.323* | 1304 |
 | Organizational learning-continuous improvement | 0.311* | 1341 | 0.287* | 1318 |
 | Teamwork within hospital units | 0.186* | 1349 | 0.297* | 1326 |
 | Communication openness | 0.168* | 1342 | 0.184* | 1311 |
 | Feedback and communication about errors | 0.413* | 1345 | 0.203* | 1315 |
 | Non-punitive response to error | 0.023 | 1323 | 0.176* | 1304 |
 | Staffing | -0.087* | 1328 | 0.222* | 1310 |
 | Hospital management support for patient safety | 0.265* | 1344 | 0.352* | 1317 |
 | Hospital handoffs and transitions | 0.175* | 1311 | 0.222* | 1284 |
 | Teamwork across hospital units | 0.209* | 1321 | 0.276* | 1292 | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | Characteristic | Routine cohort (cross-sectional) | Inception cohort (longitudinal) |
 | --- | --- | --- |
 | Patients (n) | 767 | 106 |
 | Age (years; mean ± SD) | 54.1 ± 14.9 | 50.5 ± 15.6 |
 | Sex (% female) | 79.9 | 75.2 |
 | Rheumatoid factor (% positive) | 55.3 | 78.1 |
 | Disease duration at baseline (mean ± SD) | 8.1 ± 10.6 years | 11.5 ± 12.5 weeks |
 | Duration of follow up (years; mean ± SD; range) | - | 3.2 ± 1.3; 1–7.25 |
 | Disease activity characteristics (median [1st;3rd quartile]) | At cross-section | At baseline |
 | Swollen joint count (0–28) | 3 (1;7) | 7 (4;13) |
 | Tender joint count (0–28) | 2 (0;6) | 8 (3;16) |
 | ESR (mm; normal <20) | 23 (14;55) | 49 (24;70) |
 | CRP (mg/dl; normal <1.0) | 1.1 (0.5;2.7) | 5.1 (1.9;17.0) |
 | Patient assessment of pain (mm; 0–100) | 37 (19;53) | 50 (32;66) |
 | Patient global assessment of activity (mm; 0–100) | 37 (18;58) | 51 (33;66) |
 | Evaluator global assessment of activity (mm; 0–100) | 34 (19;49) | 44 (31;58) |
 | HAQ (0–3) | 0.875 (0.25;1.5) | 0.75 (0;1.5) |
 | Larsen score | - | 1 (0;7) |
 | Completeness of data for analysis |  |  |
 | Cross-sectional correlation between composite indices (n [%]) | 767/767 (100)a | 105/106 (99.1%)b |
 | Cross-sectional correlation with HAQ scores (n [%]) | 720/767 (93.9) | 104/106 (98.1)b |
 | Discriminant validity, 1-year follow up (n [%]) | - | 91/100 (91.0%) |
 | Construct validity, 3-year follow upc (n [%]) | - | 56/80 (70.0%) | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Variable | Category/term | Ratio (95% CI) | P-value |
 | --- | --- | --- | --- |
 |

[Assistant]
<ROWSPAN=2> Age (at diagnosis) * | Age | 0.02 (0.003, 0.11) | <ROWSPAN=2> <0.001 |
 | Age | 2.12 (1.64, 2.76) |
 | Anti-Sm | No | 1 |  |
 |  | Yes | 6.31 (3.39, 11.7) | <0.001 |
 | Disease activity in vascular system | A, B | 1 |  |
 |  | C, D, E | 0.40 (0.24, 0.69) | 0.001 |
 | Hydroxychloroquine | No | 1 |  |
 |  | Yes | 1.96 (1.09, 3.53) | 0.02 |
 | Immunosuppression | No | 1 |  |
 |  | Yes | 2.96 (1.97, 4.46) | <0.001 | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <ROWSPAN=2> Feature | <ROWSPAN=2> N = 109 | <COLSPAN=3> Outcomes |
 | Improvement | Exacerbation | Death |
 | --- | --- | --- | --- | --- |
 | Means of bronchoscopic therapy (n = 53) |  | 51 | 1 | 1 |
 | Nd-YAG laser | 19/53 | <ROWSPAN=9>  | <ROWSPAN=9>  | <ROWSPAN=9>  |
 | APC | 18/53 |
 | Freezing | 15/53 |
 | Drug spraying | 12/53 |
 | Clamping | 6/53 |
 | Resection | 5/53 |
 | High-frequency electrotome cautery | 4/53 |
 | Stent implantation | 2/53 |
 | Microwaving | 1/53 |
 | Bronchoscopy/other treatments (n = 53) |  | 51 | 1 | 1 |
 | Bronchoscopic therapy alone | 20/53 | <ROWSPAN=3>  | <ROWSPAN=3>  | <ROWSPAN=3>  |
 | Combined with drug therapy | 32/53 |
 | Combined with EBRT | 1/53 |
 | Drug therapy alone (n = 25) | 25/25 | 20 | 4 | 1 |
 | EBRT/other treatments (n = 2) |  | 2 | 0 | 0 |
 | Combined with glucocorticoids | 1/2 | <ROWSPAN=2>  | <ROWSPAN=2>  | <ROWSPAN=2>  |
 | Combined with glucocorticoids + colchicine | 1/2 |
 |

[Assistant]
Surgical resection (n = 2) | 2/2 | 2 | 0 | 0 |
 | Clinical observation/symptomatic treatment (n = 27) | 27/27 | 20 | 5 | 2 |
 | Follow-up ≥ 3 months | 66/109 | 49 | 9 | 8 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | <COLSPAN=2> El Salvador (N=109) | <COLSPAN=2> Mexico (N=59) | <COLSPAN=2> Ecuador (N=64) | <COLSPAN=2> Uruguay (N=121) |
 |  | n/N | (%) | n/N | (%) | n/N | (%) | n/N | (%) |
 | --- | --- | --- | --- | --- | --- |

[Assistant]
--- | --- | --- |
 | Exists barriers | 60/106 | 56.6 | 10/49 | 20.4 | 16/60 | 26.7 | 34/107 | 31.8 |
 | <COLSPAN=9> HEALTH SYSTEM |
 | Corticosteroids availability at hospitals | 33/103 | 32.0 | 4/47 | 10.6 | 7/57 | 12.3 | 8/107 | 7.5 |
 | Corticosteroids availability at primary health care centers | 57/104 | 54.8 | 6/47 | 12.8 | 8/56 | 14.3 | 27/107 | 25.5 |
 | Availability at night hours | 22/100 | 20.2 | 7/46 | 15.2 | 6/56 | 10.7 | 21/107 | 19.6 |
 | <COLSPAN=9> PROVIDERS |
 | Fear or doubt about the side effect of the use of corticosteroids | 33/100 | 33.0 | 7/46 | 15.2 | 10/56 | 17.9 | 10/107 | 9.3 |
 | Misinformation about the correct use of the corticosteroids | 36/103 | 35.0 | 9/48 | 18.8 | 8/54 | 14.8 | 12/107 | 11.2 |
 | <COLSPAN=9> WOMEN |
 | Economic barriers to get corticosteroids | 52/104 | 50.0 | 7/46 | 15.2 | 9/57 | 15.8 | 17/107 | 15.9 |
 | Lack of personnel who can apply the corticosteroids | 24/101 | 23.8 | 3/45 | 6.7 | 3/55 | 5.5 | 19/107 | 17.8 |
 | Fear to use corticosteroids | 20/102 | 19.6 | 6/46 | 13.0 | 8/55 | 14.5 | 4/107 | 3.7 |
 | Misinformation about the correct use of the corticosteroids | 39/101 | 38.6 | 5/45 | 11.1 | 9/54 | 16.7 | 8/107 | 7.5 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> |  | No. of RCTs | Difference in mean (95% CI) | P value |
 | --- | --- | --- | --- |
 | <COLSPAN=4> LV ejection fraction |
 | Follow up < 6 months | 7 | 1.45 [0.54 to 2.36] | 0.002 |
 | Follow up > 6, < 12 months | 13 | 0.83 [–1.85 to 3.51] | 0.54 |
 | Follow up ≥ 12 months | 14 | 3.58 [1.55 to5.61] | 0.0006 |
 | <COLSPAN=4> LV end-diastolic indexes |
 | Follow up < 6 months | 6 | –4.76 [–8.19 to –1.33] | 0.006 |
 | Follow up > 6, < 12 months | 7 | –0.60 [–3.38 to 2.18] | 0.67 |
 | Follow up ≥ 12 months | 13 | –4.00 [–8.13 to 0.13] | 0.06 |
 | <COLSPAN=4> LV end-systolic indexes |
 | Follow up < 6 months | 5 | –4.29 [–11.51 to 2.92] | 0.24 |
 | Follow up > 6, < 12 months | 5 | 0.51 [–1.92 to 2.95] | 0.68 |
 | Follow up ≥ 12 months | 13 | –7.07 [–11.99 to –2.14] | 0.005 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Method of spatial variability | “High-risk” classification | # of census tracts identified as “high-risk” | # of cases residing in “high-risk” census tract | Estimated population within “high-risk” census tract |
 | --- | --- | --- | --- | --- |
 | Unadjusted IR | IR ≥ 2 per 100,000 | 744 | 1407 | 3,126,058 |
 | Standardized IR | IR ≥ 2 per 100,000 | 724 | 1376 | 3,151,260 |
 | 1% cluster detection | Detected within a cluster | 93 | 243 | 327,824 |
 | 50% cluster detection | Detected within a cluster | 259 | 412 |

[Assistant]
981,983 |
 | Reliable cluster detection | RS ≥ 0.5 and a RR ≥ 2 | 136 | 397 | 507,694 | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> | Age | Previous treatment and time passed | PSA at time of recurrence | Gleason score | Outcome +: tumor bearing nodes | Location outside of extended dissection area |
 | --- | --- | --- | --- | --- | --- |
 | 53 y | External beam, 9 y | 2.2 | 7 | − | − |
 | 68 y | Brachy therapy, 8 y | 17 | 7 | − | Para-aortic |
 | 68 y | External beam, 5 y | 4.0 | 6 | − | − |
 | 70 y | External beam, 8 y | 4.8 | 8 | + | − |
 | 63 y | Brachy therapy, 6 y | 2.1 | 6 | − | − |
 | 65 y | Brachy therapy, 7 y | 11 | 7 | − | Abdominal wall, near umbilical ligament |
 | 73 y | Brachy therapy, 2 y | 21 | 6 | + | Inguinal node (negative) |
 | 64 y | External beam, 3 y | 7 | 7 | + | − |
 | 61 y | External beam, 5 y | 12.7 | 8 | + | Para-aortic (negative) |
 | 62 y | HIFU, 2 y | 30 | 8 | − | inguinal |
 | 69 y | External beam, 3 y | 3.8 | 7 | + | Para-aortic (negative) |
 | 63 y | HIFU, 1 y | 5.4 | 6 | − | Abd. Wall, next to umbilical ligament |
 | 71 y | External beam, 6 y | 1.7 | 7 | − |  |
 | 61 y | Brachy therapy, 5 y | 2.1 | 9 | + |  | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | Characteristic | ZSQ group (n = 42) | Control group (n = 42) | P value |
 | --- | --- | --- | --- |
 | Age, yr | 32.7 ± 13.6 | 34.8 ± 14.3 | 0.46 |
 | Education, yr | 10.5 ± 3.7 | 10.6 ± 3.9 | 0.35 |
 | BMI, kg/m2 | 22.1 ± 2.6 | 22.7 ± 3.1 | 0.44 |
 | Female (n, %) | 39 (92.8%) | 38 (90.48%) | 0.67 |
 | Disease duration, yr | 4.7 ± 4.4 | 5.0 ± 4.6 | 0.79 |
 | Dosage of prednisone, mg/d | 10.2 ± 6.4 | 10.6 ± 6.6 | 0.62 |
 | SLEDAI scores | 10.5 ± 2.2 | 10.7 ± 2.1 | 0.51 |
 | SLE manifestations (n, %) |  |  |  |
 | Nephritis | 32 (76.2%) | 34 (81.0%) |  |
 | Arthritis | 20 (47.6%) | 18 (42.9%) |

[Assistant]
|
 | Dermatitis | 24 (57.1%) | 21 (50.0%) | <ROWSPAN=2> >0.05 |
 | Central nervous system | 2 (4.8%) | 1 (2.4%) |
 | Lymphopenia | 9 (21.4%) | 8 (19.0%) |  |
 | Thrombocytopenia | 6 (14.3%) | 7 (16.7%) |  |
 | Pericarditis | 1 (2.3%) | 0 (0.0%) |  |
 | Total scores of CMS | 19.5 ± 3.9 | 19.7 ± 3.9 | 0.80 |
 | Anti-dsDNA (IU/mL) | 89.8 ± 72.9 | 89.2 ± 80.5 | 0.63 |
 | C3 (g/L) | 0.8 ± 0.3 | 0.8 ± 0.2 | 0.47 |
 | C4 (g/L) | 0.2 ± 0.1 | 0.3 ± 0.1 | 0.61 |
 | IgG (g/L) | 18.7 ± 5.4 | 17.9 ± 2.8 | 0.38 |
 | NK cell activity (%) | 14.5 ± 8.8 | 14.0 ± 6.2 | 0.78 |
 | sIL-2R (pg/mL, PM) | 40.8 ± 8.6 | 40.1 ± 14.8 | 0.80 | </md>


[User] <|image|>Convert the picture to Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2-COLSPAN=2>  | <COLSPAN=2> Becoming Obesea | <COLSPAN=2> Chronically Obesea |
 | Odds Ratio | 95 % CI | Odds Ratio | 95 % CI |
 | --- | --- | --- | --- | --- | --- |
 | Gender (reference group: Boy) | Girl | 0.671** | 0.498, 0.905 | 0.55*** | 0.407, 0.744 |
 | <ROWSPAN=3> Ethnicity (reference group: White) | Asian | 0.956 | 0.624, 1.466 | 0.76 | 0.467, 1.237 |
 | Non-Hispanic Black | 0.999 | 0.63, 1.585 | 1.688* | 1.087, 2.624 |
 | Hispanic | 1.844** | 1.189, 2.862 | 2.373*** | 1.524, 3.694 |
 | School SES (reference group: High SES) | Low SES | 1.364 | 0.937, 1.986 | 1.362 | 0.952, 1.95 | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Chr | Region start | Region stop | # Probes | Nearest gene | Distance to gene (bp) | Within CpG island | Gene promoter/intragenic |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | chr1 | 228291476 | 228291715 | 5 | C1orf35 | 453 | No | – |
 | chr3 | 107810351 | 107810801 | 6 | CD47 | 415 | Yes | – |
 | chr3 | 109056339 | 109056907 | 4 | DPPA4 | 0 | No | Promoter |
 | chr4 | 124222 | 125122 | 5 | ZNF718 | 0 | Yes | Intragenic/promoter |
 | chr5 | 23506728 | 23507762 | 13 | PRDM9 | 0 | No | promoter |
 | chr5 | 134073420 | 134073589 | 5 | CAMLG | 581 | No | – |
 | chr5 | 150284292 | 150284806 | 9 | ZNF300 | 0 | Yes | Promoter |
 | chr5 | 150325572 | 150326872 | 13 | ZNF300P1 | 0 | Yes | Promoter |
 | chr6 | 168045258 | 168045898 | 5 | LOC401286 | 21624 | No | – |
 | chr6 | 34498908 | 34499514 | 5 | PACSIN1 | 0 | Yes | Intragenic |
 | chr8 | 43131250 | 43132517 | 9 | POTEA | 15068 | Yes | – |
 | chr10 | 38069509 | 38069955 | 4 | ZNF248 | 0 | Yes | Intragenic |
 | chr16 | 10479552 | 10480299 | 6 | ATF7IP2 | 0 | Yes | Promoter |
 | chr19 | 12305543 | 12306507 | 7 | LOC100289333 | 0 | Yes | Promoter |
 | chr20 | 623079 | 623431 | 4 | SRXN1 | 3837 | Yes | – |
 | chrY | 21664286 | 21665031 | 4 | BCORP1 | 0 | Yes | Promoter | </md>


[User] <|image|>Convert the photo to Markdown syntax.

[Assistant]
<md> | Population | State/Province | Country | USDA PI | Sample Size | Latitude | Longitude |
 | --- | --- | --- | --- | --- | --- | --- |
 | TX1 | Texas | USA | 413160 | 20 | 31.041 | −104.821 |
 | TX2 | Texas | USA | 664692 | 20 | 31.189 | −103.578 |
 | TX3 | Texas | USA | 468476 | 20 | 31.206 | −102.635 |
 | TX4 | Texas | USA | 468477 | 20 | 35.190 | −102.010 |
 | TX5 | Texas | USA | 468482 | 20 | 35.199 | −100.799 |
 | OK1 | Oklahoma | USA | 468486 | 12 | 35.262 | −99.669 |
 | NE1 | Nebraska | USA | 586870 | 20 | 41.063 | −98.091 |
 | NE2 | Nebraska | USA | 659440 | 20 | 41.211 | −101.649 |
 | WY1 | Wyoming | USA | 649806 | 20 | 41.418 | −104.098 |
 | MT1 | Montana | USA | 531035 | 20 | 46.585 | −108.592 |
 | MT2 | Montana | USA | 586817 | 20 | 46.795 | −105.302 |
 | ND1 | North Dakota | USA | 613750 | 20 | 46.879 | −102.789 |
 | SAS1 | Saskatchewan | Canada | 592320 | 19 | 50.048 | −104.707 |
 | SAS2 | Saskatchewan | Canada | 592311 | 15 | 50.394 | −108.480 |
 | SAS3 | Saskatchewan | Canada | 592316 | 20 | 50.660 | −105.665 | </md>


[User] <|image|>Transcribe the photo into Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> Male | <COLSPAN=2> Female |
 |  | Nicotine | AI | Nicotine | AI |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=4> Sexual behavior |
 | Prenatal exposure | Decrease | Decrease | Increase | Increase |
 | Adult exposure | Decrease | ? | Decrease | Decrease |
 | <COLSPAN=4> Anxiety/Depression |
 | Prenatal exposure | No effect | No effect | Increase | Increase |
 | Adult exposure | No effect | No effect | Decrease | Increase |
 | Hot flashes |  |  | Increase | Increase |
 | Weight gain | Decrease | Decrease | Decrease | Increase | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | Source of Variation | df | Mean Squares | Variance Component | Variance Explained |
 | --- | --- | --- | --- | --- |
 | Participants (p) | 28 | 6.597 | 0.765 | 41.69 |
 | Judges (j) | 1 | 0.508 | 0.003 | 0.16 |
 | MJV Stations (s) | 2 | 0.089 | -0.031 | 0.00 |
 | p × j | 28 | 0.118 | -0.002 | 0.00 |
 | p × s | 56 | 2.001 | 0.938 | 51.12 |
 | j × s | 2 | 0.227 | 0.004 | 0.22 |
 | pjs, e | 56 | 0.125 | 0.125 | 6.81 |
 | Total |  |  |  | 100.00 | </md>


[User] <|image|>Continue parse the figure with markdown style: <md> | Method | k-Means++ | GMM-EM | HMRF-EM | KGC | Mean Shift | FMShift |

[Assistant]
 | --- | --- | --- | --- | --- | --- | --- |
 | Avg. times (sec.) | 4.2 | 117.0 | 954.2 | 14.8 | 732.3 | 6.6 | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> |  | Loading Device | Sample Size | Survival Rate | Implantation Rate | Pregnancy Rate |
 | --- | --- | --- | --- | --- | --- |
 | Mukaida et al, 2001[8] | Cryoloop | N = 60 | 63% | -- | 31% |
 | Cho, 2002 et al [21] | EM grid | N = 21 | 83% | -- | 34% |
 | Reed et al, 2002[10] | Cryoloop | N = 54 | 100% | 15% | -- |
 | Mukaida et al, 2003[9] | Cryoloop | N = 725 | 80% | 20% | 37% |
 | Osada et al, 2003[11] | Cryotop | N = 580 | 99% | -- | 56% |
 | Stehlik et al, 2005[12] | Cryotop | N = 41 | 100% | -- | 50% |
 | Takahashi et al, 2005[19] | Cryoloop | N = 1129 | 86% | 29% | 44% |
 | Kuwayama et al, 2005[18] | Cryotip | N = 5695 | 90% | -- | 53% |
 | Liebermann et al, 2006[13] | Cryotop | N = 547 | 97% | 31% | 46% |
 | Mukaida et al, 2008[29] | Cryoloop | N = 5412 | 92% | 36% | 49% | </md>


[User] <|image|>Encode the photo in Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2> Characteristic | <COLSPAN=2> LAdCCs(N=38) | <COLSPAN=3> ADCs (N=1659) |
 | No. | % | No. | % | P |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=6> Age, yrs |
 | < 60 | 21 | 55.3 | 383 | 23.1 | <0.001 |
 | ≥ 60 | 17 | 44.7 | 1276 | 76.9 |  |
 | <COLSPAN=6> Sex |
 | Male | 26 | 68.4 | 745 | 44.9 | <0.001 |
 | Female | 12 | 31.6 | 914 | 55.1 |  |
 | <COLSPAN=6> Smoking history |
 | Never | 14 | 36.8 | 1141 | 68.8 | 0.207 |
 | Ever | 24 | 63.2 | 518 | 31.2 |  |
 | <COLSPAN=6> Stage |
 | I-II | 23 | 60.5 | 1412 | 85.1 | <0.001 |
 | III-IV | 15 | 39.5 | 247 | 14.9 |  |
 | <COLSPAN=6> T-size, cm |
 | ≥3 | 22 | 57.9 | 1284 | 77.4 | <0.001 |
 | 3<, ≥7 | 13 | 34.2 | 353 | 21.3 |  |
 | >7 | 3 | 7.9 | 22 | 1.3 |  |
 | <COLSPAN=6> N Stage |
 | N0 | 20 | 52.6 | 475 | 62.2 | <0.001 |
 | N1 | 7 | 18.4 | 85 | 11.1 |  |
 | N2 | 11 | 28.9 | 204 | 26.7 |  | </md>


[User] <|image|>Continue parse the figure with markdown style: <md> |  | <ROWSPAN=2> MHR value before/after rehabilitation | <ROWSPAN=2> ICF indicator | <ROWSPAN=2> ICF value

[Assistant]
before/after rehabilitation |
 | --- | --- | --- | --- |
 | Functional capacity of the exercise testing | 8/10 | Mobility (d4) | 0/0 |
 | Functional capacity of the exercise testing | 8/10 | Self-care (d5) | 0/0 |
 | Occupational status | Employed/Employed | Remunerative employment (d8509) | 0/0 |
 | <ROWSPAN=2> Beck Depression Inventory (BDI) | <ROWSPAN=2> 21/6 | Pain/discomfort: Emotional functions (b152) | 2/0 |
 | Anxiety/depression: Emotional functions (b152) | 2/0 | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | MLP-ANN | Hidden layer neurons | MSE | Accuracy (%) |
 | --- | --- | --- | --- |
 | 1 | 10 | 0.0605 | 75.1 |
 | 2 | 20 | 0.0867 | 61.1 |
 | 3 | 30 | 0.0380 | 71.5 |
 | 4 | 40 | 0.0581 | 74.6 |
 | 5 | 50 | 0.0439 | 80.3 |
 | 6 | 60 | 0.0516 | 79.3 |
 | 7 | 70 | 0.0614 | 78.8 |
 | 8 | 80 | 0.0355 | 87.6 |
 | 9 | 90 | 0.0604 | 75.6 |
 | 10 | 100 | 0.0403 | 84.5 | </md>